# EDGAR Filing Document

**Accession Number:** 0001877322
**File Stem:** 0001877322-25-000152
**Filing Date:** 2025-10
**Character Count:** 166319
**Document Hash:** 7c42be40044bd55c17b4ec0ada23fd63
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001877322-25-000152.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001877322-25-000152

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 82

**CONFORMED PERIOD OF REPORT**: 20251003

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ESAB Corp
- **CENTRAL INDEX KEY:** 0001877322
- **STANDARD INDUSTRIAL CLASSIFICATION:** GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 870923837
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41297
- **FILM NUMBER:** 251426699

**BUSINESS ADDRESS:**
- **STREET 1:** 909 ROSE AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** NORTH BETHESDA
- **STATE:** MD
- **ZIP:** 20852
- **BUSINESS PHONE:** (302) 252-9160

**MAIL ADDRESS:**
- **STREET 1:** 909 ROSE AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** NORTH BETHESDA
- **STATE:** MD
- **ZIP:** 20852

?xml version='1.0' encoding='ASCII'? esab-20251003

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

---

| | |
|:---|:---|
| **FORM** | **10-Q** |

---

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended October 3, 2025**

**OR** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission file number - 001-41297** 

**ESAB Corporation**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **87-0923837** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification Number)** |
| **909 Rose Avenue, 8th Floor** | |
| **North Bethesda, Maryland** | **20852** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

---

| | |
|:---|:---|
| **(301)** | **323-9099** |
| **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | ESAB | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑ &nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer ☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer ☐

Smaller reporting company ☐&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☑

As of October 22, 2025, there were 60,710,966 shares of the registrant's common stock, par value $0.001 per share, outstanding.

------

**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
| | **Page** |
| **PART I - FINANCIAL INFORMATION** | |
| Item 1. Financial Statements | <u>[2](#icf405b831be445378a26ec56e4687ef2_13)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated and Condensed Statements of Operations | <u>[2](#icf405b831be445378a26ec56e4687ef2_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated and Condensed Statements of Comprehensive Income | <u>[3](#icf405b831be445378a26ec56e4687ef2_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated and Condensed Balance Sheets | <u>[4](#icf405b831be445378a26ec56e4687ef2_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated and Condensed Statements of Equity | <u>[5](#icf405b831be445378a26ec56e4687ef2_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated and Condensed Statements of Cash Flows | <u>[7](#icf405b831be445378a26ec56e4687ef2_28)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes to Consolidated and Condensed Financial Statements | <u>[7](#icf405b831be445378a26ec56e4687ef2_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 1. Organization and Basis of Presentation | <u>[8](#icf405b831be445378a26ec56e4687ef2_34)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 2. Discontinued Operations | <u>[9](#icf405b831be445378a26ec56e4687ef2_37)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 3. Acquisitions | <u>[9](#icf405b831be445378a26ec56e4687ef2_40)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 4. Revenue | <u>[11](#icf405b831be445378a26ec56e4687ef2_46)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 5. Earnings per Share from Continuing Operations | <u>[11](#icf405b831be445378a26ec56e4687ef2_49)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 6. Income Taxes | <u>[12](#icf405b831be445378a26ec56e4687ef2_55)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 7. Inventories, Net | <u>[12](#icf405b831be445378a26ec56e4687ef2_58)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 8. Accrued and Other Liabilities | <u>[12](#icf405b831be445378a26ec56e4687ef2_58)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 9. Benefit Plans | <u>[13](#icf405b831be445378a26ec56e4687ef2_61)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 10. Debt | <u>[13](#icf405b831be445378a26ec56e4687ef2_64)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 11. Derivatives | <u>[15](#icf405b831be445378a26ec56e4687ef2_67)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 12. Financial Instruments and Fair Value Measurements | <u>[17](#icf405b831be445378a26ec56e4687ef2_70)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 13. Equity | <u>[19](#icf405b831be445378a26ec56e4687ef2_73)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 14. Commitments and Contingencies | <u>[22](#icf405b831be445378a26ec56e4687ef2_76)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 15. Segment Information | &nbsp;&nbsp;<u>[23](#icf405b831be445378a26ec56e4687ef2_79)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note 16. Subsequent Events | &nbsp;&nbsp;<u>[25](#icf405b831be445378a26ec56e4687ef2_82)</u> |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>[26](#icf405b831be445378a26ec56e4687ef2_85)</u> |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | &nbsp;&nbsp;<u>[40](#icf405b831be445378a26ec56e4687ef2_160)</u> |
| Item 4. Controls and Procedures | <u>[41](#icf405b831be445378a26ec56e4687ef2_163)</u> |
| **PART II - OTHER INFORMATION** |  |
| Item 1. Legal Proceedings | <u>[42](#icf405b831be445378a26ec56e4687ef2_169)</u> |
| Item 1A. Risk Factors | <u>[42](#icf405b831be445378a26ec56e4687ef2_172)</u> |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | <u>[42](#icf405b831be445378a26ec56e4687ef2_175)</u> |
| Item 3. Defaults Upon Senior Securities | <u>[42](#icf405b831be445378a26ec56e4687ef2_178)</u> |
| Item 4. Mine Safety Disclosures | <u>[42](#icf405b831be445378a26ec56e4687ef2_181)</u> |
| Item 5. Other Information | <u>[42](#icf405b831be445378a26ec56e4687ef2_184)</u> |
| Item 6. Exhibits | <u>[43](#icf405b831be445378a26ec56e4687ef2_190)</u> |
| **SIGNATURES** | <u>[44](#icf405b831be445378a26ec56e4687ef2_193)</u> |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ESAB CORPORATION**

**CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS**

**Dollars in thousands, except per share amounts**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| Net sales | $727845 | $673250 | $2121569 | $2070047 |
| Cost of sales | 458545 | 419460 | 1331020 | 1290915 |
| Gross profit | 269300 | 253790 | 790549 | 779132 |
| Selling, general and administrative expense | 158335 | 145900 | 454756 | 434537 |
| Restructuring and other related charges | 4347 | 1875 | 10236 | 8572 |
| Operating income | 106618 | 106015 | 325557 | 336023 |
| Pension settlement loss |  |  |  | 12155 |
| Interest expense and other, net | 23584 | 16894 | 61365 | 49925 |
| Income from continuing operations before income taxes | 83034 | 89121 | 264192 | 273943 |
| Income tax expense | 17694 | 18074 | 56476 | 54463 |
| Net income from continuing operations | 65340 | 71047 | 207716 | 219480 |
| Loss from discontinued operations, net of taxes | (8819) | (1214) | (13259) | (3684) |
| Net income | 56521 | 69833 | 194457 | 215796 |
| Income attributable to noncontrolling interest, net of taxes | (1674) | (1593) | (5364) | (4698) |
| Net income attributable to ESAB Corporation | $54847 | $68240 | $189093 | $211098 |
| *Earnings (loss) per share – basic* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations | $1.05 | $1.14 | $3.33 | $3.54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on discontinued operations | (0.15) | (0.02) | (0.22) | (0.06) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income per share – basic | $0.90 | $1.12 | $3.11 | $3.48 |
| *Earnings (loss) per share – diluted* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations | $1.04 | $1.13 | $3.29 | $3.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on discontinued operations | (0.14) | (0.02) | (0.22) | (0.06) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income per share – diluted | $0.90 | $1.11 | $3.07 | $3.44 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

See Notes to Consolidated and Condensed Financial Statements.

------

**ESAB CORPORATION**

**CONSOLIDATED AND CONDENSED STATEMENTS OF COMPREHENSIVE INCOME**

**Dollars in thousands**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| Net income | $56521 | $69833 | $194457 | $215796 |
| Other comprehensive (loss) income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation, net of tax expense (benefit) of $947, $(2871), $(10625) and $(924) | (6087) | 63675 | 175461 | 23764 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on derivatives designated and qualifying as cash flow hedges, net of tax benefit of $—, $(911), $(497) and $(1155) |  | (3130) | (1816) | (3968) |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit pension and other post-retirement plan activity, net of tax expense of $50, $23, $158 and $270 | 250 | 343 | 773 | 1299 |
| Other comprehensive (loss) income | (5837) | 60888 | 174418 | 21095 |
| Comprehensive income | 50684 | 130721 | 368875 | 236891 |
| Comprehensive income attributable to noncontrolling interest | (348) | (2302) | (4418) | (4715) |
| Comprehensive income attributable to ESAB Corporation | $50336 | $128419 | $364457 | $232176 |

---

See Notes to Consolidated and Condensed Financial Statements.

------

**ESAB CORPORATION**

**CONSOLIDATED AND CONDENSED BALANCE SHEETS**

**Dollars in thousands, except share and per share amounts**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **December 31, 2024** |
| **ASSETS** | | |
| &nbsp;&nbsp;&nbsp;CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $218219 | $249358 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade receivables, less allowance for credit losses of $23,557 and $23,850 | 460469 | 370321 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 503722 | 403711 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 64291 | 55665 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 87020 | 69327 |
| &nbsp;&nbsp;&nbsp;Total current assets | 1333721 | 1148382 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net | 357927 | 298347 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 1962752 | 1651993 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 684439 | 487993 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease assets - right of use | 133751 | 89859 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 396813 | 357401 |
| Total assets | 4869403 | 4033975 |
| **LIABILITIES AND EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of debt | 2175 | 15000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 342214 | 318493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 324685 | 298558 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 669074 | 632051 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 1334123 | 1060739 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 704179 | 532936 |
| Total liabilities | 2707376 | 2225726 |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock - $0.001 par value - 600,000,000 shares authorized, 60,709,740 and 60,517,574 shares outstanding as of October 3, 2025 and December 31, 2024, respectively | 61 | 61 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1900871 | 1901337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 769226 | 597180 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (554210) | (729574) |
| Total ESAB Corporation equity | 2115948 | 1769004 |
| Noncontrolling interest | 46079 | 39245 |
| Total equity | 2162027 | 1808249 |
| Total liabilities and equity | $4869403 | $4033975 |

---

See Notes to Consolidated and Condensed Financial Statements.

------

**ESAB CORPORATION**

**CONSOLIDATED AND CONDENSED STATEMENTS OF EQUITY**

**Dollars in thousands, except share and per share amounts (Unaudited)** 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-in Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Noncontrolling Interest** | **Total** |
| | **Shares** | **Amount** | **Additional Paid-in Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Noncontrolling Interest** | **Total** |
| **Balance at December 31, 2024** | 60517574 | $61 | $1901337 | $597180 | $(729574) | $39245 | $1808249 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  | 67363 |  | 2469 | 69832 |
| &nbsp;&nbsp;Dividends declared ($0.08 per share) |  |  |  | (4868) |  |  | (4868) |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling owners |  |  |  |  |  | (1168) | (1168) |
| &nbsp;&nbsp;Other comprehensive income, net of tax benefit of $4,808 |  |  |  |  | 77717 | 118 | 77835 |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 105162 |  | 512 |  |  |  | 512 |
| **Balance at April 4, 2025** | 60622736 | 61 | 1901849 | 659675 | (651857) | 40664 | 1950392 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  | 66883 |  | 1221 | 68104 |
| &nbsp;&nbsp;Dividends declared ($0.10 per share) |  |  |  | (6091) |  |  | (6091) |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling owners |  |  |  |  |  | (6) | (6) |
| &nbsp;&nbsp;Other comprehensive income, net of tax benefit of $7,153 |  |  |  |  | 102158 | 262 | 102420 |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 74050 |  | (3048) |  |  |  | (3048) |
| **Balance at July 4, 2025** | 60696786 | 61 | 1898801 | 720467 | (549699) | 42141 | 2111771 |
| &nbsp;&nbsp;Net income |  |  |  | 54847 |  | 1674 | 56521 |
| &nbsp;&nbsp;Dividends declared ($0.10 per share) |  |  |  | (6088) |  |  | (6088) |
| &nbsp;&nbsp;Distributions and purchases relating to noncontrolling owners |  |  |  |  |  | 3590 | 3590 |
| &nbsp;&nbsp;Other comprehensive income, net of tax expense of $997 |  |  |  |  | (4511) | (1326) | (5837) |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 12954 |  | 2070 |  |  |  | 2070 |
| **Balance at October 3, 2025** | 60709740 | $61 | $1900871 | $769226 | $(554210) | $46079 | $2162027 |

---

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-in Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Noncontrolling Interest** | **Total** |
| | **Shares** | **Amount** | **Additional Paid-in Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Loss** | **Noncontrolling Interest** | **Total** |
| **Balance at December 31, 2023** | 60295634 | $60 | $1881054 | $350557 | $(624272) | $40258 | $1647657 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  | 59951 |  | 1643 | 61594 |
| &nbsp;&nbsp;Dividends declared ($0.06 per share) |  |  |  | (3641) |  |  | (3641) |
| &nbsp;&nbsp;Other comprehensive loss, net of tax expense of $2,029 |  |  |  |  | (23389) | (323) | (23712) |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 128787 |  | 480 |  |  |  | 480 |
| **Balance at March 29, 2024** | 60424421 | 60 | 1881534 | 406867 | (647661) | 41578 | 1682378 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  | 82907 |  | 1462 | 84369 |
| &nbsp;&nbsp;Dividends declared ($0.08 per share) |  |  |  | (4856) |  |  | (4856) |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling owners |  |  |  |  |  | (1218) | (1218) |
| &nbsp;&nbsp;Other comprehensive loss, net of tax benefit of $79 |  |  |  | **—** | (15712) | (369) | (16081) |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 14417 |  | 4833 | **—** |  |  | 4833 |
| **Balance at June 28, 2024** | 60438838 | 60 | 1886367 | 484918 | (663373) | 41453 | 1749425 |
| &nbsp;&nbsp;Net income |  |  |  | 68240 |  | 1593 | 69833 |
| &nbsp;&nbsp;Dividends declared ($0.08 per share) |  |  |  | (4858) |  |  | (4858) |
| &nbsp;&nbsp;Distributions to noncontrolling owners |  |  | 2860 |  | (1706) | (3155) | (2001) |
| &nbsp;&nbsp;Other comprehensive loss, net of tax benefit of $3,759 |  |  |  |  | 60179 | 709 | 60888 |
| &nbsp;&nbsp;&nbsp;Common stock-based award activity | 5408 |  | 4438 |  |  |  | 4438 |
| **Balance at September 27, 2024** | 60444246 | $60 | $1893665 | $548300 | $(604900) | $40600 | $1877725 |

---

See Notes to Consolidated and Condensed Financial Statements.

------

**ESAB CORPORATION**

**CONSOLIDATED AND CONDENSED STATEMENTS OF CASH FLOWS**

**Dollars in thousands**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** |
| **Cash flows from operating activities:** | | |
| &nbsp;&nbsp;Net income | $194457 | $215796 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization and other impairment charges | 58731 | 50028 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net gain on sale of property, plant and equipment | (5697) | (1060) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 12542 | 14473 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax (benefit) expense | (7707) | 2394 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash interest expense | 1882 | 2259 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension settlement loss |  | 12155 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade receivables, net | (50381) | (39075) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | (28924) | (31651) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (9893) | 16895 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating assets and liabilities | (1496) | (13691) |
| **Net cash provided by operating activities** | 163514 | 228523 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (27654) | (27071) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of property, plant and equipment | 4731 | 3452 |
| &nbsp;&nbsp;&nbsp;Acquisitions, net of cash received | (439669) | (86537) |
| &nbsp;&nbsp;&nbsp;Other investing | 539 | (4058) |
| **Net cash used in investing activities** | (462053) | (114214) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from borrowings on Senior Notes |  | 700000 |
| &nbsp;&nbsp;&nbsp;Proceeds from borrowings on revolving credit facilities and other | 359591 | 205000 |
| &nbsp;&nbsp;&nbsp;Repayments of borrowings on Term Loans | (10000) | (597500) |
| &nbsp;&nbsp;&nbsp;Repayments of borrowings on revolving credit facilities and other | (90442) | (236623) |
| &nbsp;&nbsp;&nbsp;Payment of debt issuance costs |  | (10423) |
| &nbsp;&nbsp;&nbsp;Payment of dividends | (15821) | (12135) |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling interest holders | (3057) | (2644) |
| &nbsp;&nbsp;&nbsp;Other financing | (13008) | (5099) |
| **Net cash provided by financing activities** | 227263 | 40576 |
| Effect of foreign exchange rates on Cash and cash equivalents | 40137 | (3218) |
| **(Decrease) increase in Cash and cash equivalents** | (31139) | 151667 |
| Cash and cash equivalents, beginning of period | 249358 | 102003 |
| **Cash and cash equivalents, end of period** | $218219 | $253670 |

---

See Notes to Consolidated and Condensed Financial Statements.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

**1. Organization and Basis of Presentation**

Founded in 1904, ESAB Corporation ("ESAB" or the "Company") is a focused premier industrial compounder. ESAB provides its partners with fabrication technology advanced equipment, consumables, gas control equipment, robotics and digital solutions. The Company's rich history of innovative products, workflow solutions and its business management system, ESAB Business Excellence ("EBX"), enables the Company's purpose of *Shaping the world we imagine*<sup>TM</sup>. The Company's products are utilized to solve challenges in a wide range of industries, including cutting, joining and automated welding and gas control. The Company conducts its operations through two reportable segments. These segments consist of the "Americas," which includes operations in North America and South America, and "EMEA & APAC," which includes Europe, Middle East, India, Africa and Asia Pacific.

The Company's fiscal year ends December 31. The Company's third quarter ends on the last business day of the 13<sup>th</sup> complete week after the end of the prior quarter. As used herein, the third quarter results for 2025 and 2024 refer to the 13-week periods ended October 3, 2025 and September 27, 2024, respectively.

*Russia and Ukraine Conflict*

The invasion of Ukraine by Russia and the sanctions imposed in response have increased the level of economic and political uncertainty. While ESAB continues to closely monitor the situation and evaluate options, the Company is meeting current contractual obligations while addressing applicable laws and regulations. For the three and nine months ended October 3, 2025, Russia represented approximately 6% and 5%, respectively, of the Company's Net sales and approximately $3 million and $9 million, respectively, of its Net income. Russia also has approximately 5% of the Company's total net assets as of October 3, 2025, including approximately $48 million of Cash and cash equivalents that may be subject to delays in withdrawing from Russia, based upon the current environment at that time. In case of the disposition of the Russia business, a portion of goodwill would need to be allocated and disposed of at the relative fair value attributable to the Russia business. Russia has a cumulative translation loss of approximately $110 million as of October 3, 2025, which would be realized upon a transition out. The Company is closely monitoring developments in Ukraine and Russia. Changes in laws and regulations or other factors impacting the Company's ability to fulfill contractual obligations could have an adverse effect on the results of operations and cash flows.

*Basis of Presentation* 

The Consolidated and Condensed Financial Statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with the accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading.

The Consolidated and Condensed Financial Statements reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company's financial position and results of operations as of and for the periods indicated. Intercompany transactions and accounts are eliminated in consolidation. Certain line items on our Consolidated and Condensed Statements of Cash Flows have been reclassified to conform to the current presentation.

In the normal course of business, the Company incurs research and development costs related to new product development, which are expensed as incurred and included in Selling, general and administrative expense on the Company's Consolidated and Condensed Statements of Operations. Research and development costs were $10.5 million and $31.1 million during the three and nine months ended October 3, 2025, respectively, and $9.2 million and $29.0 million for the three and nine months ended September 27, 2024, respectively. These amounts do not include development and application engineering costs incurred in conjunction with fulfilling customer orders and executing customer projects, nor do they include costs related to securing third party product rights. The Company expects to continue making significant expenditures for research and development to maintain and improve its competitive positions.

The accompanying interim Consolidated and Condensed Financial Statements and the related notes should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K"), filed with the SEC on February 20, 2025.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

**2. Discontinued Operations**

The Company holds certain asbestos-related contingencies and insurance coverages from divested businesses for which it does not have an interest in the ongoing operations. The Company has classified asbestos-related activity included in its Consolidated and Condensed Statements of Operations as part of Loss from discontinued operations, net of taxes. This activity consists primarily of expected settlements, legal and administrative expenses associated with the above liabilities. Discontinued operations consist primarily of Selling, general and administrative expense, with an associated tax impact that is considered immaterial. See Note 14, "Commitments and Contingencies" for further information.

Cash used in operating activities related to discontinued operations was $3.6 million and $10.8 million for the three and nine months ended October 3, 2025, respectively, and $3.6 million and $12.1 million for the three and nine months ended September 27, 2024, respectively.

**3. Acquisitions**

The Company continually evaluates potential acquisitions that either strategically fit with its existing portfolio or expand its portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for using the acquisition method and have resulted in the recognition of goodwill in the Company's financial statements. This goodwill arises because the purchase prices for these businesses exceeded the fair value of acquired identifiable net assets. This excess is attributable to a variety of factors, including, but not limited to, the anticipated future earnings and cash flow potential of the acquired businesses; prevailing market multiples applied to earnings and cash flows in comparable transactions; the competitive nature of the acquisition processes; the strategic benefits of accelerating market entry or enhancing existing product offerings without incurring the time, cost and risk associated with internal development; and the complementary fit and expected synergies these businesses contribute to the Company's existing operations.

Under the acquisition method of accounting, the Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities from information obtained during due diligence and through other sources. As the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, the Company is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue, revenue growth rates, royalty rates and customer attrition rates. These assumptions are forward looking and could be affected by future economic and market conditions. The Company engages third-party valuation specialists who provide guidance on the Company's critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions. The Company makes appropriate adjustments to purchase price allocations prior to completion of the applicable measurement period, as required. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment.

The following table describes the Company's 2025 acquisition activity, for which it acquired 100% of the equity and voting interest of each acquired entity.

---

| | | | |
|:---|:---|:---|:---|
| **Acquisition Date** | **Company** | **Description** | **Segment** |
| April 30, 2025 | Bavaria Schweisstechnik ("Bavaria") | A European provider of submerged-arc welding applications | EMEA & APAC |
| June 4, 2025 | DeltaP s.r.l. ("DeltaP") | A European provider of medical central gas systems and aftermarket services | EMEA & APAC |
| July 9, 2025 | Aktiv Technologies Private Limited ("Aktiv") | An industrial gas equipment manufacturer based in India | EMEA & APAC |
| August 22, 2025 | EWM GmbH ("EWM") | A Global leader in heavy industrial welding equipment and advanced automation | EMEA & APAC |

---

The following table summarizes the preliminary allocation of the purchase price to the assets acquired and liabilities assumed for the nine months ended October 3, 2025. These amounts, including inventories, deferred taxes, intangible assets, and property, plant and equipment, are determined based upon certain valuations and studies that have yet to be finalized. Accordingly, the assets acquired and liabilities assumed, as detailed below, are subject to adjustment once the detailed analyses are completed. None of the goodwill is expected to be deductible for tax purposes.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| | **EWM** | **All Others** | **Total** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Cash and cash equivalents | $10349 | $6803 | $17152 |
| Inventories, net | 39903 | 7662 | 47565 |
| Property, plant and equipment, net | 31470 | 6284 | 37754 |
| Goodwill<sup>(1)</sup> | 162926 | 65865 | 228791 |
| Identifiable intangible assets<sup>(2)</sup> | 137141 | 43938 | 181079 |
| &nbsp;&nbsp;Customer relationships<sup>(3)</sup> | 96433 | 35771 | 132204 |
| &nbsp;&nbsp;Trade names | 20536 | 6294 | 26830 |
| &nbsp;&nbsp;Technology | 20172 | 1873 | 22045 |
| Deferred tax liability | (35605) | (12006) | (47611) |
| Other, net<sup>(4)</sup> | (11438) | (890) | (12328) |
| Preliminary purchase price consideration | 334746 | 117656 | 452402 |

---

 

<sup>(1)</sup> Goodwill for "All Others" includes approximately $39 million for Bavaria and $17 million for Aktiv.

<sup>(2)</sup> Definite-lived intangibles are subject to estimated weighted-average useful lives ranging from five to twenty years.

<sup>(3)</sup> Customer relationships for "All Others" includes approximately $23 million for Bavaria.

<sup>(4)</sup> Includes current and non-current amounts and non-controlling interest.

For the three and nine months ended October 3, 2025, the above acquisitions added approximately $27 million and $35 million, respectively, to Net sales. The Company incurred approximately $1 million and $10 million of acquisition-related costs for the acquisitions completed in 2025 in the three and nine months ended October 3, 2025, respectively. These costs were expensed in Selling, general and administrative expense in the Consolidated and Condensed Statements of Operations.

For a description of the Company's acquisition activity for the year ended December 31, 2024, reference is made to the financial statements as of and for the year ended December 31, 2024 and Note 5, "Acquisitions" thereto in the Company's 2024 Annual Report.

**4. Revenue**

The Company provides fabrication technology advanced equipment, consumables, gas control equipment, robotics and digital solutions. Substantially all revenue is recognized at a point in time. The Company disaggregates its revenue into the following product groups:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Equipment | $249948 | $219415 | $714375 | $665934 |
| Consumables | 477897 | 453835 | 1407194 | 1404113 |
|  | $727845 | $673250 | $2121569 | $2070047 |

---

The sales mix in the above table is relatively consistent across both reportable segments. The consumables product grouping generally has less production complexity and shorter production cycles than equipment products.

Given the nature of the business, the total amount of unsatisfied performance obligations with an original contract duration of greater than one year as of October 3, 2025 is immaterial. In some circumstances, customers are billed in advance of revenue recognition, resulting in contract liabilities. As of December 31, 2024 and December 31, 2023, total contract liabilities were $26.4 million and $31.2 million, respectively, and were included in Accrued liabilities on the Consolidated and Condensed Balance Sheets. During the three and nine months ended October 3, 2025, revenue recognized that was included in the contract liabilities balance at the beginning of the year was $1.9 million and $15.5 million, respectively. During the three and nine months ended September 27, 2024, revenue recognized that was included in the contract liabilities balance at the beginning of the year was $1.3 million and $22.6 million, respectively. As of October 3, 2025 and September 27, 2024, total contract liabilities were $27.2 million and $27.8 million, respectively.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

*Allowance for Credit Losses*

A summary of the activity in the Company's allowance for credit losses included within Trade receivables in the Consolidated and Condensed Balance Sheets is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** |
| | **Balance at<br>Beginning<br>of Period** | **Charged to Expense, net** | **Write-Offs and Deductions** | **Foreign<br>Currency<br>Translation** | **Balance at<br>End of<br>Period** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Allowance for credit losses | $23850 | $1138 | $(2871) | $1440 | $23557 |

---

**5. Earnings per Share from Continuing Operations**

The Company has unvested share-based payment awards with a right to receive non-forfeitable dividends, which are considered participating securities. The Company allocates earnings to participating securities and computed earnings per share using the two-class method as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(In thousands, except share and per share data)** | **(In thousands, except share and per share data)** | **(In thousands, except share and per share data)** | **(In thousands, except share and per share data)** |
| *Computation of earnings per share from continuing operations – basic:* |  |  |  |  |
| &nbsp;&nbsp;Income from continuing operations attributable to ESAB Corporation<sup>(1)</sup> | $63666 | $69454 | $202352 | $214782 |
| &nbsp;&nbsp;Distributed and undistributed earnings allocated to nonvested shares | (131) | (305) | (546) | (1052) |
| &nbsp;&nbsp;Income from continuing operations attributable to common stockholders | $63535 | $69149 | $201806 | $213730 |
| &nbsp;&nbsp;Weighted-average shares of Common stock outstanding – basic | 60703560 | 60439818 | 60668678 | 60406056 |
| &nbsp;&nbsp;Income per share from continuing operations – basic | $1.05 | $1.14 | $3.33 | $3.54 |
| *Computation of earnings per share from continuing operations – diluted:* |  |  |  |  |
| &nbsp;&nbsp;Income from continuing operations attributable to common stockholders | $63535 | $69149 | $201806 | $213730 |
| &nbsp;&nbsp;&nbsp;Weighted-average shares of Common stock outstanding – basic | 60703560 | 60439818 | 60668678 | 60406056 |
| &nbsp;&nbsp;Net effect of potentially dilutive securities<sup>(2)</sup> | 534781 | 646311 | 608723 | 644791 |
| &nbsp;&nbsp;&nbsp;Weighted-average shares of Common stock outstanding – dilution | 61238341 | 61086129 | 61277401 | 61050847 |
| &nbsp;&nbsp;&nbsp;Net income per share from continuing operations – diluted | $1.04 | $1.13 | $3.29 | $3.50 |

---

 

<sup>(1)</sup> Net income from continuing operations attributable to ESAB Corporation for the respective periods is calculated using Net income from continuing operations, less Income attributable to noncontrolling interest, net of taxes, of $1.7 million and $5.4 million for the three and nine months ended October 3, 2025, respectively, and $1.6 million and $4.7 million for the three and nine months ended September 27, 2024, respectively.

<sup>(2)</sup> Potentially dilutive securities include stock options, performance-based restricted stock units and non-performance-based restricted stock units.

**6. Income Taxes** 

During the three and nine months ended October 3, 2025, Income from continuing operations before income taxes was $83.0 million and $264.2 million, respectively, while Income tax expense was $17.7 million and $56.5 million, respectively. The effective tax rate was 21.3% and 21.4% for the three and nine months ended October 3, 2025, respectively. The effective tax rate differed from the 2025 U.S. federal statutory rate of 21.0% primarily due to the impact of a law change in a foreign jurisdiction and withholding tax offset by a release of a valuation allowance in a foreign jurisdiction.

During the three and nine months ended September 27, 2024, Income from continuing operations before income taxes was $89.1 million and $273.9 million, respectively, while Income tax expense was $18.1 million and $54.5 million, respectively. The effective tax rate was 20.3% and 19.9% for the three and nine months ended September 27, 2024, respectively. The

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

effective tax rate differed from the 2024 U.S. federal statutory rate of 21.0% primarily due to a favorable final ruling in a tax case in a foreign jurisdiction and an agreement with a taxing authority on the treatment of subsidy income in a foreign jurisdiction.

**7. Inventories, Net**

Inventories, net consisted of the following:

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **December 31, 2024** |
| | **(In thousands)** | **(In thousands)** |
| Raw materials | $171915 | $151248 |
| Work in process | 51161 | 41698 |
| Finished goods | 321539 | 251994 |
|  | 544615 | 444940 |
| Allowance for excess, slow-moving and obsolete inventory | (40893) | (41229) |
|  | $503722 | $403711 |

---

**8. Accrued and Other Liabilities**

Accrued and Other liabilities in the Consolidated and Condensed Balance Sheets consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **December 31, 2024** | **December 31, 2024** |
| | **Current** | **Noncurrent** | **Current** | **Noncurrent** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Accrued taxes and deferred tax liabilities | $54338 | $199396 | $46395 | $151642 |
| Compensation and related benefits | 82674 | 53244 | 80451 | 48350 |
| Asbestos liability | 43335 | 279473 | 40779 | 253287 |
| Contract liabilities | 27244 |  | 26390 |  |
| Lease liabilities | 22569 | 108171 | 21459 | 66042 |
| Warranty liability | 13325 |  | 12794 |  |
| Third-party commissions | 16109 |  | 17346 |  |
| Restructuring liability | 6994 | 27 | 4732 | 374 |
| Accrued interest | 18966 |  | 8077 |  |
| Other | 39131 | 63868 | 40135 | 13241 |
|  | $324685 | $704179 | $298558 | $532936 |

---

*Accrued Warranty Liability*

A summary of the activity in the Company's warranty liability included in Accrued liabilities in the Company's Consolidated and Condensed Balance Sheets is as follows:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** |
| | **(In thousands)** | **(In thousands)** |
| Warranty liability, beginning of period | $12794 | $12606 |
| &nbsp;&nbsp;Accrued warranty expense | 6526 | 8026 |
| &nbsp;&nbsp;Changes in estimates related to pre-existing warranties | 906 | 1829 |
| &nbsp;&nbsp;Cost of warranty service work performed | (9102) | (8507) |
| &nbsp;&nbsp;Foreign exchange translation effect and other | 2201 | (40) |
| Warranty liability, end of period | $13325 | $13914 |

---

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

*Accrued Restructuring Liability*

The Company's restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company's restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated and Condensed Balance Sheets is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** |
| | **Balance at Beginning of Period** | **Charges** | **Payments** | **Foreign Currency Translation** | **Balance at End of Period** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Termination benefits<sup>(1)</sup> | $3845 | $7089 | $(5240) | $703 | $6397 |
| Facility closure costs and other<sup>(2)</sup> | 1261 | 3147 | (3593) | (191) | 624 |
|  | $5106 | $10236 | $(8833) | $512 | $7021 |

---

 

<sup>(1)</sup> Includes severance and other termination benefits, including outplacement services.

<sup>(2)</sup> Includes the cost of relocating associates, relocating equipment and other costs in connection with the closure and optimization of facilities and product lines.

**9. Benefit Plans**

The Company sponsors various defined benefit plans and other post-retirement benefits plans, including health and life insurance, for certain eligible employees or former employees.

During the nine months ended September 27, 2024, the Company recognized a non-cash pension settlement loss of $12.2 million related to the transfer of plan assets to a third party as part of externalizing the risk associated with a foreign defined benefit plan. This amount is reflected in Pension settlement loss in the Consolidated and Condensed Statements of Operations.

**10. Debt**

The following table shows the components of the Company's debt:

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **December 31, 2024** |
| | **(In thousands)** | **(In thousands)** |
| Term loans | $375000 | $385000 |
| Senior unsecured notes | 700000 | 700000 |
| Revolving credit facility | 260000 |  |
| Other debt | 8888 |  |
| Total debt | 1343888 | 1085000 |
| Current portion of debt | (2175) | (15000) |
| Unamortized deferred financing fees | (7590) | (9261) |
| Long-term debt | $1334123 | $1060739 |

---

*Senior Notes, Term Loans and Revolving Credit Facility*

On April 4, 2022, the Company entered into a credit agreement (as amended and restated from time-to-time, the "Credit Agreement") that initially consisted of a $750 million revolving credit facility (the "Revolving Facility") with a maturity date of April 4, 2027, a Term A-1 loan with an initial aggregate principal amount of $400 million (the "Term Loan A-1 Facility"), with a maturity date of April 4, 2027; and a $600 million 364-day senior term loan facility (the "Term Loan A-2 Facility") with a maturity date of April 3, 2023. The Revolving Facility contains a $300 million foreign currency sublimit and a $50 million swing line loan sub-facility.

On June 28, 2022, the Company amended and restated the Credit Agreement by entering into Amendment No. 2 to the Credit Agreement ("Credit Agreement Amendment"). The Credit Agreement Amendment provides for a $600 million term loan facility (the "Term Loan A-3 Facility," collectively the "Term Facilities" with Term A-1 Facility and Term A-2 Facility) with a maturity date of April 3, 2025 to refinance the Company's existing Term Loan A-2 Facility. Also on June 28, 2022, the

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

Company borrowed the entire $600 million under Term Loan A-3 Facility to fund the repayment of the Term Loan A-2 Facility.

On April 9, 2024, the Company issued $700 million in aggregate principal amount of 6.25% senior notes due 2029 (the "Senior Notes") governed by an indenture (the "Indenture"). The Company used the net proceeds from the Senior Notes to pay off its Term Loan A-3 Facility and pay fees associated with the offering.

After the quarter ended October 3, 2025, on October 16, 2025, the Company entered into an Amended and Restated Credit Agreement that, among other things, provides for (i) a senior term loan A facility in an aggregate principal amount of $350 million, and (ii) a senior revolving credit facility in the amount of $1.05 billion to replace the Company's existing $400 million Term Loan A-1 Facility and $750 million Revolving Facility and pay off the outstanding principal and interest thereunder. Both facilities mature on October 16, 2030, subject to a springing maturity date under certain circumstances. The new covenants and applicable interest rate under the Amended and Restated Credit Agreement are substantially similar to the prior agreement. Refer to "Note 16, Subsequent Events" for further details.

As of October 3, 2025, the Company's debt primarily consisted of the following facilities:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A $750 million Revolving Facility with a maturity date of April 4, 2027, with $260 million drawn;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Term Loan A-1 Facility with an aggregate principal amount of $375 million and a maturity date of April 4, 2027; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Senior Notes with an aggregate principal amount of $700 million and a maturity date of April 15, 2029.

The Credit Agreement and the Indenture contain customary covenants. These covenants limit the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments or pay dividends. In addition, the Credit Agreement requires that the Company maintains certain financial covenants and the Company was in compliance with all of its debt covenants as of October 3, 2025. The Credit Agreement and the Indenture contain various events of default (including failure to comply with the covenants under the Credit Agreement and related agreements) and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Term A-1 Facility, Senior Notes and the Revolving Facility. Certain United States subsidiaries of the Company have agreed to guarantee the obligations of the Company under the Credit Agreement and Senior Notes.

Loans made under the Term A-1 Facility will bear interest, at the election of the Company, at either the base rate (as defined in the Credit Agreement) or at the term Secured Overnight Financing Rate ("SOFR") plus an adjustment (as defined in the Credit Agreement), in each case, plus the applicable interest rate margin. Loans made under the Revolving Facility will bear interest, at the election of the Company, at either the base rate or, (i) in the case of loans denominated in dollars, the term SOFR plus an adjustment or the daily simple SOFR plus an adjustment, (ii) in the case of loans denominated in euros, the adjusted Euro Interbank Offered Rate ("EURIBOR") rate and, (iii) in the case of loans denominated in sterling, Sterling Overnight Index Average ("SONIA") plus an adjustment (as all such rates are defined in the Credit Agreement Amendment), in each case, plus the applicable interest rate margin. The applicable interest rate margin changes based upon the Company's total leverage ratio (consolidated total debt divided by EBITDA, as defined in the credit agreement and ranging from 1.125% to 1.750% or in the case of the base rate margin, 0.125% to 0.750%). Each swing line loan denominated in dollars will bear interest at the base rate plus the applicable interest rate margin.

To manage exposures to currency exchange rates and interest rates arising in Long-term debt, the Company entered into interest rate and cross-currency swap agreements. Refer to Note 11, "Derivatives" for additional information.

As of October 3, 2025, the weighted-average interest rate of borrowings under the Credit Agreement and Indenture was 5.55%, including the net impact from the cross-currency swaps and excluding accretion of deferred financing fees, and there was $490 million of borrowing capacity available under the Revolving Facility, subject to the Company meeting financial covenants and other requirements.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

*Other Indebtedness* 

In addition to the debt agreements discussed above, the Company also has the ability to incur approximately $50 million of indebtedness pursuant to certain uncommitted credit lines, consisting of an uncommitted credit line that the Company has used from time to time in the past for short-term working capital needs.

The Company is party to letter of credit facilities with an aggregate capacity of $113.3 million. Total letters of credit of $32.4 million were outstanding as of October 3, 2025.

*Deferred Financing Fees*

The Company had total deferred financing fees of $8.0 million included in its Consolidated and Condensed Balance Sheets as of October 3, 2025, which will be charged to Interest expense and other, net, over the term of the related debt instruments. The costs associated with the Term Facilities and Senior Notes noted above will be amortized over the contractual term of the related facility and the costs associated with these will be amortized over the life of the Credit Agreement or the Indenture. Of the $8.0 million, $0.4 million of deferred financing fees relating to the Revolving Facility are included in Other assets and $7.6 million of deferred financing fees relating to the Term Facilities and Senior Notes are recorded as a contra-liability within Long-term debt.

**11. Derivatives**

The Company uses derivative instruments to manage exposures to currency exchange rates and interest rates arising in connection with long-term debt and the normal course of business. The Company has established policies and procedures that govern the risk management of these exposures. Both at inception and on an ongoing basis, the derivative instruments that qualify for hedge accounting are assessed as to their effectiveness, when applicable.

The Company is subject to the credit risk of counterparties to derivative instruments. Counterparties include a number of major banks and financial institutions. None of the concentrations of risk with an individual counterparty was considered significant as of October 3, 2025. The Company does not expect any counterparties to fail to meet their obligations. The Company records derivatives in the Consolidated and Condensed Balance Sheets at fair value.

*Cash Flow Hedges*

On July 14, 2022, the Company entered into two interest rate swap agreements to manage interest rate risk exposure. The aggregate notional amount of these contracts was $600 million and they were set to mature in April 2025. These interest rate swap agreements utilized by the Company effectively modify the Company's exposure to interest rate risk by converting a portion of the Company's floating-rate debt to a fixed rate of 3.293%, plus a spread, thus reducing the impact of interest-rate changes on future interest expense. The applicable spread may vary between 1.125% to 1.750%, depending on the total leverage ratio of the Company.

In March 2024, the Company settled one of the interest rate swaps associated with the Company's floating-rate debt and received $5.5 million in connection with that settlement. The termination of the interest rate swap was related to the repayment of the Term A-3 Facility in April 2024. Refer to Note 10, "Debt" for further information. As this interest rate swap was designated as a cash flow hedge, $5.5 million was deferred in accumulated other comprehensive loss ("AOCL") and was recognized in earnings over the period the originally forecasted hedged transaction impacted earnings. The remaining $300 million swap was hedged against the remaining floating-rate debt through its maturity on April 3, 2025. Therefore, the Company does not have any interest rate swaps outstanding as of October 3, 2025.

The cash inflows and outflows associated with the Company's interest rate swap agreement designated as cash flow hedges were classified in cash flows from operating activities in the accompanying Consolidated and Condensed Statements of Cash Flows.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

The effects of designated cash flow hedges on the Company's Consolidated and Condensed Statements of Operations consisted of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|<br>**Derivative Type** |<br>**Gain Recognized in the Consolidated and Condensed Statements of Operations** | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Interest rate swap agreement(s) | Interest expense and other, net | $— | $(1910) | $(1414) | $(7680) |

---

*Net Investment Hedges* 

On July 22, 2022, the Company entered into two cross-currency swap agreements, set to mature in April 2025, to partially hedge its net investment in its Euro-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Euro. The cross-currency swap agreements included provisions to exchange fixed-rate payments in U.S. Dollar for fixed-rate payments in Euro and were designated and qualified as a net investment hedge. These contracts had a Euro aggregate notional amount of approximately €270 million and a U.S. Dollar aggregate notional amount of $275 million.

Prior to the maturity of these two cross-currency swaps, on June 25, 2024, the Company de-designated these swaps and entered into four new cross-currency swaps for the same above notional amounts that mature in October 2026.

On August 22, 2024, the Company entered into two additional cross-currency swap agreements, set to mature in October 2026. These contracts have a Euro aggregate notional amount of approximately €90 million and a U.S. dollar aggregate notional amount of $100 million. These swaps are designated and accounted for as a net investment hedge.

The changes in the spot rate of these instruments are recorded in AOCI in equity, partially offsetting the foreign currency translation adjustment of the Company's related net investment that is also recorded in AOCI. The Company uses the spot method of assessing hedge effectiveness and as such, the initial value of the hedge components excluded from the assessment of effectiveness is recognized in the Interest expense and other, net line item in the Consolidated and Condensed Statements of Operations under a systematic and rational method over the life of the cross-currency swap agreements. Any ineffective portions of net investment hedges are reclassified from AOCI into earnings during the period of change. Due to the de-designation transaction above on June 25, 2024, the Company will keep the balance in AOCI related to the original derivative for the duration that the investment is held. The Company did not have any ineffectiveness related to net investment hedges during the nine months ended October 3, 2025.

The cash inflows and outflows associated with the excluded components of the Company's cross-currency swap agreements designated as net investment hedges are classified in operating activities in the accompanying Consolidated and Condensed Statements of Cash Flows.

The effects of the excluded components of designated net investment hedges on the Company's Consolidated and Condensed Statements of Operations consisted of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|<br>**Derivative Type** |<br>**Gain Recognized in the Consolidated and Condensed Statements of Operations** | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Cross-currency swap agreements | Interest expense and other, net | $(903) | $(1061) | $(1687) | $(3415) |

---

The table below shows the fair value of the derivatives recognized in the Consolidated and Condensed Balance Sheets:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**October 3, 2025** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**October 3, 2025** | **December 31, 2024** | **December 31, 2024** |
|<br>**Designated as Hedging Instruments** | **Other Liabilities** | **Other Assets** | **Other Liabilities** | **Other Assets** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Cross-currency swap agreements | $49741 | $— | $1830 | $— |
| Interest rate swap agreement |  |  |  | 842 |
|  | $49741 | $— | $1830 | $842 |

---

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

*Derivatives Not Designated as Hedging Instruments* 

The Company has certain foreign currency contracts that are not designated as hedges. As of October 3, 2025 and December 31, 2024, the Company had foreign currency contracts related to purchases and sales with notional values of $130.2 million and $178.7 million, respectively.

The table below shows the fair value of derivative instruments not designated in a hedging relationship recognized in the Consolidated and Condensed Balance Sheets:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**October 3, 2025** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**October 3, 2025** | **December 31, 2024** | **December 31, 2024** |
|<br>**Not Designated as Hedging Instruments** | **Accrued Liabilities** | **Other Current Assets** | **Accrued Liabilities** | **Other Current Assets** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Foreign currency contracts | $387 | $2209 | $379 | $255 |

---

The amounts in the table above as of October 3, 2025 reflect the fair value of the Company's foreign currency contracts on a net basis where allowable under master netting agreements. Had these amounts been recognized on a gross basis, the impact would have been a $0.4 million increase in Other current assets with a corresponding increase in Accrued liabilities.

The Company recognized the following in its Consolidated and Condensed Financial Statements related to its derivative instruments not designated in a hedging relationship:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|<br>**Foreign Currency Contracts** | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Change in unrealized gains (losses) | $660 | $(1220) | $1945 | $(591) |
| Realized gains | $670 | $919 | $2260 | $903 |

---

The above gains or losses on foreign currency contracts are usually offset by foreign exchange exposure on cash and intercompany positions, all of which are recognized in Interest expense and other, net, in the Consolidated and Condensed Statements of Operations.

**12. Financial Instruments and Fair Value Measurements**

The carrying values of financial instruments, including Trade receivables and Accounts payable, approximate their fair values due to their short-term maturities. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.

A summary of the Company's assets and liabilities that are measured at fair value for each fair value hierarchy level for the periods presented is as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** | **October 3, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Level<br>One** | **Level<br>Two** | **Level<br>Three** | **Total** | **Level<br>One** | **Level<br>Two** | **Level<br>Three** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| *Assets:* |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Cash equivalents | $14997 | $— | $— | $14997 | $8990 | $— | $— | $8990 |
| &nbsp;&nbsp;Foreign currency contracts |  | 2614 |  | 2614 |  | 657 |  | 657 |
| &nbsp;&nbsp;Interest rate swap agreement |  |  |  |  |  | 842 |  | 842 |
| &nbsp;&nbsp;Deferred compensation plans |  | 6895 |  | 6895 |  | 5242 |  | 5242 |
|  | $14997 | $9509 | $— | $24506 | $8990 | $6741 | $— | $15731 |
| *Liabilities:* |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency contracts | $— | $792 | $— | $792 | $— | $781 | $— | $781 |
| &nbsp;&nbsp;Cross-currency swap agreements |  | 49741 |  | 49741 |  | 1830 |  | 1830 |
| &nbsp;&nbsp;Deferred compensation plans |  | 6895 |  | 6895 |  | 5242 |  | 5242 |
|  | $— | $57428 | $— | $57428 | $— | $7853 | $— | $7853 |

---

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

The Company measures the fair value of foreign currency contracts, cross-currency swap agreements and interest rate swap agreement(s) using Level Two inputs based on observable spot and forward rates in active markets. Additionally, the fair value of derivatives designated in hedging relationships includes a credit valuation adjustment to appropriately incorporate nonperformance risk for the Company and the respective counterparty. For the nine months ended October 3, 2025, the impact of the credit valuation adjustment on the Company's derivatives is immaterial. Refer to Note 11, "Derivatives" for additional information. There were no transfers in or out of Level One, Two or Three during the nine months ended October 3, 2025.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

**13. Equity**

*Share Repurchase Program*

On August 13, 2024, the Board of Directors authorized and approved a stock repurchase program to repurchase up to five million shares of the Company's Common stock, par value $0.001 per share, from time-to-time on the open market, in privately negotiated transactions or as may otherwise be determined by the Company's management in its discretion. No repurchases of the Company's Common stock have been made through the nine months ended October 3, 2025. The timing and amount of any shares repurchased will be determined by the Company's management based on its evaluation of market conditions, applicable legal requirements and other factors. There is no term associated with the repurchase authorization.

*Accumulated Other Comprehensive Loss*

The following tables present the changes in the balances of each component of AOCL including reclassifications out of AOCL for the nine months ended October 3, 2025 and September 27, 2024. All amounts are net of tax and noncontrolling interest, if any.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** |
| | **Net Unrecognized Pension and Other Post-Retirement Benefit Cost** | **Foreign Currency Translation Adjustment** | **Net Investment Hedges** | **Cash Flow Hedges** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Balance at December 31, 2024** | $(50352) | $(679791) | $(1247) | $1816 | $(729574) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net actuarial loss | 48 |  |  |  | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (421) | 94613 | (15371) |  | 78821 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on long-term intra-entity foreign currency transactions |  | 391 |  |  | 391 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on cash flow hedges |  |  |  | 16 | 16 |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (373) | 95004 | (15371) | 16 | 79276 |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)(2)</sup> | 273 |  |  | (1832) | (1559) |
| &nbsp;&nbsp;Net current period Other comprehensive (loss) income | (100) | 95004 | (15371) | (1816) | 77717 |
| **Balance at April 4, 2025** | (50452) | (584787) | (16618) |  | (651857) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (431) | 117446 | (25027) |  | 91988 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on long-term intra-entity foreign currency transactions |  | 9968 |  |  | 9968 |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (431) | 127414 | (25027) |  | 101956 |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)</sup> | 202 |  |  |  | 202 |
| &nbsp;&nbsp;Net current period Other comprehensive (loss) income | (229) | 127414 | (25027) |  | 102158 |
| **Balance at July 4, 2025** | (50681) | (457373) | (41645) |  | (549699) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (56) | (7176) | 3244 |  | (3988) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on long-term intra-entity foreign currency transactions |  | (773) |  |  | (773) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (56) | (7949) | 3244 |  | (4761) |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)</sup> | 250 |  |  |  | 250 |
| &nbsp;&nbsp;Net current period Other comprehensive (loss) income | 194 | (7949) | 3244 |  | (4511) |
| **Balance at October 3, 2025** | $(50487) | $(465322) | $(38401) | $— | $(554210) |

---

 

<sup>(1)</sup> The amounts on this line within the Net Unrecognized Pension and Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost.

<sup>(2)</sup> The amount within the Cash Flow Hedges column is a component of Interest expense and other, net. See Note 11, "Derivatives" for additional details.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** | **Accumulated Other Comprehensive Loss Components** |
| | **Net Unrecognized Pension and Other Post-Retirement Benefit Cost** | **Foreign Currency Translation Adjustment** | **Net Investment Hedges** | **Cash Flow Hedges** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| **Balance at December 31, 2023** | $(59805) | $(554622) | $(17215) | $7370 | $(624272) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 243 | (38265) | 4995 |  | (33027) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on long-term intra-entity foreign currency transactions |  | 7996 |  |  | 7996 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on cash flow hedges |  |  |  | 3920 | 3920 |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 243 | (30269) | 4995 | 3920 | (21111) |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)(2)</sup> | 629 |  |  | (2907) | (2278) |
| &nbsp;&nbsp;Net current period Other comprehensive income (loss) | 872 | (30269) | 4995 | 1013 | (23389) |
| **Balance at March 29, 2024** | (58933) | (584891) | (12220) | 8383 | (647661) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 6 | (23042) | 686 |  | (22350) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on long-term intra-entity foreign currency transactions |  | 8162 |  |  | 8162 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on cash flow hedges |  |  |  | 811 | 811 |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 6 | (14880) | 686 | 811 | (13377) |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)(2)</sup> | 327 |  |  | (2662) | (2335) |
| &nbsp;&nbsp;Net current period Other comprehensive income (loss) | 333 | (14880) | 686 | (1851) | (15712) |
| **Balance at June 28, 2024** | (58600) | (599771) | (11534) | 6532 | (663373) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (291) | 63336 | (8945) |  | 54100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on long-term intra-entity foreign currency transactions |  | 8866 |  |  | 8866 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on cash flow hedges |  |  |  | (1230) | (1230) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | (291) | 72202 | (8945) | (1230) | 61736 |
| &nbsp;&nbsp;Amounts reclassified from Accumulated other comprehensive loss<sup>(1)(2)</sup> | 343 |  |  | (1900) | (1557) |
| &nbsp;&nbsp;Purchase related to noncontrolling interest |  | (1706) |  |  | (1706) |
| &nbsp;&nbsp;Net current period Other comprehensive income (loss) | 52 | 70496 | (8945) | (3130) | 58473 |
| **Balance at September 27, 2024** | $(58548) | $(529275) | $(20479) | $3402 | $(604900) |

---

 

<sup>(1)</sup> The amounts on this line within the Net Unrecognized Pension and Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost.

<sup>(2)</sup> The amount within the Cash Flow Hedges column is a component of Interest expense and other, net. See Note 11, "Derivatives" for additional details.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

**14. Commitments and Contingencies** 

*Asbestos Contingencies* 

Certain entities are the legal obligor, or owner, for certain asbestos obligations including long-term asbestos insurance assets, long-term asbestos insurance receivables, accrued asbestos liabilities, long-term asbestos liabilities, asbestos indemnity expenses, asbestos-related defense costs and asbestos insurance recoveries related to the asbestos obligations of the Company's legacy industrial businesses. As a result, the Company holds certain asbestos-related contingencies and insurance coverages.

These subsidiaries are each one of many defendants in a large number of lawsuits that claim personal injury as a result of exposure to asbestos from products manufactured or used with components that are alleged to have contained asbestos. Such components were acquired from third-party suppliers, and were not manufactured by any of the Company's subsidiaries, nor were the subsidiaries producers or direct suppliers of asbestos. The manufactured products that are alleged to have contained or used asbestos generally were provided to meet the specifications of the subsidiaries' customers, including the U.S. Navy. The subsidiaries settle asbestos claims for amounts the Company considers reasonable given the facts and circumstances of each claim. The annual average settlement payment per asbestos claimant has fluctuated during the past several years while the number of cases has remained substantially even versus prior year. The Company expects such settlement value fluctuations to continue in the future based upon, among other things, the number and type of claims settled in a particular period and the jurisdictions in which such claims arise. To date, the majority of settled claims have been dismissed for no payment to plaintiffs.

The Company has classified asbestos-related activity in Loss from discontinued operations, net of taxes in the Consolidated and Condensed Statements of Operations. Refer to the 2024 Form 10-K for further detail on this classification.

The Company has projected each subsidiary's future asbestos-related liability costs with regard to pending and future unasserted claims based upon the Nicholson methodology. The Nicholson methodology is a standard approach used by experts and has been accepted by numerous courts. It is ESAB's policy to record a liability for asbestos-related liability costs for the longest period of time that ESAB management can reasonably estimate.

The Company believes that it can reasonably estimate the asbestos-related liability for pending and future claims that will be resolved in the next 15 years and has recorded that liability at its best estimate. While it is reasonably possible that the subsidiaries will incur costs after this period, the Company does not believe the reasonably possible loss or a range of reasonably possible losses is estimable at the current time. Accordingly, no accrual has been recorded for any costs that may be paid after the next 15 years. Defense costs associated with asbestos-related liabilities as well as costs incurred related to efforts to recover insurance from the subsidiaries' insurers are expensed as incurred.

Each subsidiary has separate insurance coverage that was acquired prior to Company ownership. The Company estimates the insurance assets for each subsidiary based upon the applicable policy language, expected recoveries and allocation methodologies, and law pertaining to the affected subsidiary's insurance policies.

Asbestos-related claims activity since December 31 is as follows:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** |
| | **(Number of claims)** | **(Number of claims)** |
| Claims unresolved, beginning of period | 13758 | 13648 |
| Claims filed<sup>(1)</sup> | 3814 | 3782 |
| Claims resolved<sup>(2)</sup> | (3415) | (3978) |
| Claims unresolved, end of period | 14157 | 13452 |

---

 

<sup>(1)</sup> Claims filed include all asbestos claims for which notification has been received or a file has been opened.

<sup>(2)</sup> Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

The Company's Consolidated and Condensed Balance Sheets included the following amounts related to asbestos-related litigation:

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **December 31, 2024** |
| | **(In thousands)** | **(In thousands)** |
| Long-term asbestos insurance asset<sup>(1)</sup> | $257020 | $234951 |
| Long-term asbestos insurance receivable<sup>(1)</sup> | 17626 | 16961 |
| Accrued asbestos liability<sup>(2)</sup> | 43335 | 40779 |
| Long-term asbestos liability<sup>(3)</sup> | $279473 | $253287 |

---

 

<sup>(1)</sup> Included in Other assets in the Consolidated and Condensed Balance Sheets.

<sup>(2)</sup> Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company's insurers, which is included in Accrued liabilities in the Consolidated and Condensed Balance Sheets.

<sup>(3)</sup> Included in Other liabilities in the Consolidated and Condensed Balance Sheets.

Management's analyses are based on currently known facts and assumptions. Projecting future events, such as new claims to be filed each year, the average cost of resolving each claim, coverage issues among layers of insurers, the method in which losses will be allocated to the various insurance policies, interpretation of the effect on coverage of various policy terms and limits and their interrelationships, the continuing solvency of various insurance companies, the amount of remaining insurance available, as well as the numerous uncertainties inherent in asbestos litigation could cause the actual liabilities and insurance recoveries to be higher or lower than those projected or recorded that could materially affect the Company's financial condition, results of operations or cash flow. From time to time, other asbestos allegations related to the Company's legacy industrial businesses are brought against the Company. Management currently believes no loss is probable or estimable for these other matters.

*General Litigation*

The Company is involved in various pending legal proceedings arising out of the ordinary course of the Company's business. None of these legal proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, and the litigation and claims described in the preceding paragraphs, management of the Company believes that it will either prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded when incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these legal proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company.

**15. Segment Information**

ESAB is a focused premier industrial compounder. ESAB provides its partners with fabrication technology advanced equipment, consumables, gas control equipment, welding robotics and digital solutions. The Company conducts its operations through two reportable segments. These segments consist of the "Americas," which includes operations in North America and South America, and "EMEA & APAC," which includes Europe, Middle East, India, Africa and Asia Pacific.

The Company's management considers its Chief Operating Decision Maker ("CODM") as Shyam Kambeyanda, President, Chief Executive Officer and Director. The Company's management and CODM evaluate the operating results of each reportable segment, including assessment of profit or loss, performance and allocation of resources, based upon Net sales and Adjusted EBITDA, which represents Net income from continuing operations excluding the impact of Income tax expense, Interest expense and other, net, Pension settlement loss, Restructuring and other related charges, acquisition - amortization and other related charges and depreciation and other amortization. Segment results reflect the allocation of overhead costs, which primarily consist of Selling, general and administrative expense.

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

The Company's segment results were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| *Net sales:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $292729 | $288816 | $856123 | $894628 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 435116 | 384434 | 1265446 | 1175419 |
|  | $727845 | $673250 | $2121569 | $2070047 |
| *Cost of sales:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $180572 | $174396 | $522738 | $546287 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 277973 | 245064 | 808282 | 744628 |
|  | $458545 | $419460 | $1331020 | $1290915 |
| *Allocated operating expense:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $13878 | $16901 | $41395 | $50620 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 23256 | 25835 | 74415 | 76514 |
|  | $37134 | $42736 | $115810 | $127134 |
| *Other operating expense:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $41024 | $38150 | $123452 | $119570 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 51644 | 45469 | 134392 | 134883 |
|  | $92668 | $83619 | $257844 | $254453 |
| *Adjusted EBITDA*<sup>(1)</sup>*:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $57255 | $59369 | $168538 | $178151 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 82243 | 68066 | 248357 | 219394 |
|  | $139498 | $127435 | $416895 | $397545 |
| *Depreciation, amortization and other impairment charges:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $8998 | $7704 | $25846 | $23208 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 12887 | 9394 | 32885 | 26820 |
|  | $21885 | $17098 | $58731 | $50028 |
| *Capital expenditures:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $4218 | $5516 | $12334 | $11745 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 6962 | 5118 | 15320 | 15326 |
|  | $11180 | $10634 | $27654 | $27071 |

---

 

<sup>(1)</sup> The following is a reconciliation of Net income from continuing operations to Adjusted EBITDA.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Net income from continuing operations | $65340 | $71047 | $207716 | $219480 |
| Income tax expense | 17694 | 18074 | 56476 | 54463 |
| Interest expense and other, net | 23584 | 16894 | 61365 | 49925 |
| Pension settlement loss |  |  |  | 12155 |
| Restructuring and other related charges<sup>(1)</sup> | 4347 | 1875 | 10236 | 8572 |
| Acquisition - amortization and other related charges<sup>(2)</sup> | 16489 | 10064 | 47682 | 25571 |
| Depreciation and other amortization | 12044 | 9481 | 33420 | 27379 |
| Adjusted EBITDA | $139498 | $127435 | $416895 | $397545 |

---

------

**ESAB CORPORATION** 

**NOTES TO CONSOLIDATED AND CONDENSED FINANCIAL STATEMENTS — (Continued)**

 **(Unaudited)**

 

<sup>(1)</sup> Includes severance and other termination benefits, including outplacement services, as well as the cost of relocating associates, relocating equipment, lease termination expenses, impairment of long-lived assets and other costs in connection with the closure and optimization of facilities and product lines.

<sup>(2)</sup> Includes transaction, diligence and integration expenses totaling $6.1 million and $20.4 million for the three and nine months ended October 3, 2025, respectively, and $2.5 million and $3.1 million for the three and nine months ended September 27, 2024, respectively. Additionally, it includes amortization of intangibles and fair value charges on acquired inventories totaling $10.3 million and $27.3 million three and nine months ended October 3, 2025, respectively, and $7.6 million and $22.4 million for the three and nine months ended September 27, 2024, respectively.

---

| | | |
|:---|:---|:---|
| | **October 3, 2025** | **December 31, 2024** |
| | **(In thousands)** | **(In thousands)** |
| *Investments in equity method investees:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 31372 | 28885 |
|  | $31372 | $28885 |
| *Total assets:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $1833862 | $1796167 |
| &nbsp;&nbsp;&nbsp;&nbsp;EMEA & APAC | 3035541 | 2237808 |
|  | $4869403 | $4033975 |
| *Property, plant and equipment, net*<sup>(1)</sup>*:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | $72276 | $73036 |
| &nbsp;&nbsp;&nbsp;&nbsp;Czech Republic | 71784 | 55554 |
| &nbsp;&nbsp;&nbsp;&nbsp;India | 31714 | 31506 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mexico | 23081 | 20495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Poland | 19731 | 17227 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other foreign countries | 139341 | 100529 |
|  | $357927 | $298347 |

---

 

<sup>(1)</sup> As the Company does not allocate all long-lived assets, specifically intangible assets, to each individual country, evaluation of long-lived assets in total is impracticable.

**16. Subsequent Events**

The dividend of $6.1 million included in Accrued liabilities in the Consolidated and Condensed Balance Sheets at October 3, 2025 was paid on October 17, 2025 to stockholders of record as of October 3, 2025.

On October 16, 2025, the Company entered into an Amended and Restated Credit Agreement, by and among the Company, as the lead borrower, the other loan parties from time to time party thereto, including certain subsidiaries of the Company identified therein, as guarantors, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent (the "A&R Credit Agreement"). The A&R Credit Agreement, among other things, provides for (i) a senior term loan A facility in an aggregate principal amount of $350 million, and (ii) a senior revolving credit facility in the amount of $1.05 billion to pay off the outstanding principal and interest on the Company's existing $400 million Term Loan A-1 Facility and replace the Company's $750 million Revolving Facility. Both facilities mature on October 16, 2030, subject to a springing maturity date under certain circumstances.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

*The following discussion of the financial condition and results of operations of ESAB Corporation ("ESAB," the "Company," "we," "our" and "us") should be read in conjunction with the Consolidated and Condensed Financial Statements and related footnotes included in Part I. Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q for the quarterly period ended October 3, 2025 (this "Form 10-Q") and the Consolidated Financial Statements and related footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"). You should review the discussion titled "Special Note Regarding Forward-Looking Statements" for a discussion of forward-looking statements. Our actual results, outcomes or the timing of results or outcomes could differ materially from those discussed in the forward-looking statements.*

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS** 

All statements contained in this Form 10-Q that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Form 10-Q is filed with the Securities and Exchange Commission (the "SEC"). Statements that could be deemed to be forward-looking statements, include statements regarding: the impact of the war in Ukraine and the conflict in the Middle East and the resulting escalating geopolitical tensions on our business; projections of revenue, profit margins, expenses, tax provisions and tax rates, earnings or losses from operations, impact of foreign exchange rates, cash flows, pension and benefit obligations and funding requirements, synergies or other financial items; plans, strategies and objectives of our management for future operations, including statements relating to potential acquisitions, compensation plans or purchase commitments; developments, performance, industry or market rankings relating to products or services; future economic conditions or performance, including the impact of inflationary pressures, tariffs and trade policies, foreign exchange fluctuations and commodity prices; the outcome of outstanding claims or legal proceedings, including asbestos-related liabilities and insurance coverage litigation; potential gains and recoveries of costs; assumptions underlying any of the foregoing; and any other statement that addresses activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements may be, but are not always, characterized by terminology such as "believe," "anticipate," "should," "would," "could," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy," "targets," "aims," "seeks," "sees" or similar expressions. These statements are based on assumptions and assessments made by our management as of the filing date of this Form 10-Q in light of their experience and perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties and actual results or outcomes, or the timing of results or outcomes, could differ materially due to numerous factors, including but not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* the war in Ukraine and conflict in the Middle East, escalating geopolitical tensions and the related impact on energy supplies and prices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in the general economy, including disruptions caused by geopolitical conflicts, as well as the cyclical nature of the markets we serve;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• supply chain constraints and backlogs and risks affecting the availability and prices for raw materials, parts and components, including tariffs and trade disputes, labor shortages and inefficiencies, freight and logistical challenges and inflation in raw material, part, component, freight and delivery costs and our ability to increase our prices to account for increased costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• volatility in the commodity markets and certain commodity prices, including oil and steel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to identify, finance, acquire and successfully integrate attractive acquisition targets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our exposure to unanticipated liabilities resulting from acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• significant movements in foreign currency exchange rates or inflation rates;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of natural or man-made disasters, adverse or extreme weather events or conditions, epidemics, pandemics and other global health events;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability and the ability of our customers to access required capital at a reasonable cost;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to accurately estimate the cost of or realize savings from our restructuring programs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the amount of, and our ability to estimate and manage, our asbestos-related liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the solvency of our insurers and the likelihood of their payment for asbestos-related costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• material disruptions at any of our manufacturing facilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• noncompliance with various laws and regulations associated with our international operations, including anti-bribery laws, export control regulations and sanctions and embargoes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with our international operations, including risks from trade protection measures and other changes in trade relations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with the representation of our employees by trade unions and works councils;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our exposure to product liability claims;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential costs and liabilities associated with environmental, health and safety laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to maintain, protect and defend our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract and retain our employees, including the loss of key members of our leadership team;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restrictions in our financing arrangements that may limit our flexibility in operating our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impairment in the value of intangible assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the funding requirements or obligations of our defined benefit pension plans and other postretirement benefit plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new regulations and customer preferences reflecting an increased focus on environmental, social and governance issues, including regulations related to climate change and the use of conflict minerals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• service interruptions, data corruption, cyber-based attacks or network security breaches affecting our electronic information systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks arising from changes in technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the competitive environment in our industries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in our tax rates, realizability of deferred tax assets or exposure to additional income tax liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to manage and grow our business and execution of our business and growth strategies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the level of capital investment and expenditures by our customers in our strategic markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our financial performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties and delays in integrating or fully realizing projected cost savings and benefits of our acquisitions; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other risks and factors set forth under "Risk Factors" in Part I. Item 1A. in our 2024 Form 10-K and in Part II. Item 1A in our Form 10-Q for the quarterly period ended April 4, 2025 (the "2025 Q1 Form 10-Q").

See Part I. Item 1.A. "Risk Factors" in our 2024 Form 10-K and in Part II. Item 1A in our 2025 Q1 Form 10-Q for a further discussion regarding reasons that actual results and outcomes, and the timing of results and outcomes, may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Forward-looking statements speak only as of the date of this Form 10-Q. We do not assume any obligation to update or revise any forward-looking statement, whether because of new information, future events and developments or otherwise.

**Overview**

Please see Part I. Item 1. "Business" in our 2024 Form 10-K, for a discussion of ESAB's objectives and methodologies for delivering stockholder value.

We are a focused premier industrial compounder. Our rich history of innovative products, workflow solutions and our business system, ESAB Business Excellence ("EBX"), enables our purpose of *Shaping the world we imagine*<sup>TM</sup>*.* We conduct our operations through two reportable segments. These segments consist of the "Americas," which includes operations in North America and South America, and "EMEA & APAC," which includes Europe, Middle East, India, Africa and Asia Pacific. We serve a global customer base across multiple markets through a combination of direct sales and third-party distribution channels. Our customer base is highly diversified in the industrial end markets.

**Outlook**

We believe that we are well positioned to grow our businesses organically over the long term by enhancing our product offerings and expanding our customer base. We believe our business mix is well balanced between sales in high growth and developed markets, and equipment and consumables. We believe that our geographic and end market diversity helps mitigate the effects from cyclical industrial market exposures. Given this balance, management does not use indices other than general economic trends and business initiatives to predict the overall outlook for the Company. Instead, our individual businesses monitor key competitors and customers, including to the extent possible their sales, to gauge relative performance and outlook for the future.

We expect strategic acquisitions to contribute to our growth. We believe that our extensive experience of acquiring and effectively integrating acquisition targets should enable us to capitalize on future opportunities. We believe our recent acquisitions are aligned with this strategic direction. Refer to Note 3, "Acquisitions" in the accompanying Notes contained elsewhere in this Form 10-Q for additional information.

Because our products and services are available worldwide, we rely on a global supply chain to source raw materials, parts and components. The majority of our sales are derived from international operations and, as such, we are subject to specific risks associated with changes in the United States policy regarding international trade and other retaliatory trade measures that the United States and foreign governments may take, including the imposition of tariffs, sanctions, export or import controls and other measures that restrict international trade. The United States has announced significant new tariffs on imports from a wide range of countries, including China, which was followed by retaliatory tariffs by China and a number of countries and a cycle of further retaliatory announcements and trade actions. While certain of the tariffs have been and may be delayed, others have taken or may take effect. Further, tariffs announced or imposed by the United States could be altered or delayed through presidential action, bilateral negotiations, judicial orders or congressional actions, and tariffs announced by other countries can be affected by similar developments. These and future changes in tariffs and trade policies have resulted and could result in additional costs and pricing pressures, supply chain disruptions, volatile or unpredictable customer spending patterns and increased economic or geopolitical risks, any or all of which could adversely affect our business, financial condition and results of operations, perhaps materially or in ways that we cannot predict.

We are actively monitoring and evaluating these developments and the potential impacts of trade policy and tariffs on our business, supply chain and results of operations. We maintain operations worldwide, including in the jurisdictions impacted by the recently announced and contemplated tariffs. If tariffs continue to be maintained at current levels, and/or the United States government or foreign governments impose further retaliatory tariffs or other trade restrictive measures in response, then in addition to the efforts reflected in the discussion that follows, we expect that such actions could negatively impact our revenue growth and margins in future periods through increased supply chain costs, decreased demand and other adverse economic

------

impacts. The net effect of these actions on our company will depend on our ability to successfully mitigate and offset their impact, which efforts may not be effective. If we are unable to mitigate these risks through supply chain adjustments, pricing strategies or other measures, our business could be negatively affected and produce additional impacts. Please refer to Part I. Item 1.A. "Risk Factors" in our 2024 Form 10-K and in Part II. Item 1A in our 2025 Q1 Form 10-Q for additional information. The full impact of the matters noted above on the Company, our customers and suppliers, the overall economy and capital markets remains uncertain.

The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for the three and nine months ended October 3, 2025 and September 27, 2024.

**Results of Operations**

The following discussion of our Results of Operations addresses the comparison of the periods presented. Our management evaluates the operating results of each of its reportable segments based upon Net sales, Adjusted EBITDA and Core adjusted EBITDA as defined in the "Non-GAAP Measures" section.

*Items Affecting Comparability of Reported Results*

The comparability of our operating results for the three and nine months ended October 3, 2025 and September 27, 2024 is affected by the following significant factors:

<u>Russia and Ukraine Conflict</u>

The invasion of Ukraine by Russia and the sanctions and other actions taken by governments in response to this crisis have increased the level of economic and political uncertainty. Refer to Note 1, "Organization and Basis of Presentation" in the accompanying Notes contained elsewhere in this Form 10-Q as well as Part I. Item 1.A. "Risk Factors" section of the 2024 Form 10-K, as updated by our 2025 Q1 Form 10-Q, for additional information.

<u>Tariffs</u>

The Company continues to actively monitor the changes in United States policy regarding international trade, including the recent progress in reaching or progressing international trade agreements with major counterparties. As reflected in the discussions that follow, the United States policy regarding international trade and actions taken in response to it have had a variety of impacts on our results of operations during 2025, including decreased sales levels and increased raw material costs. For additional information on the risks of United States policy regarding international trade to the Company's operations, refer to the "Part II. Item 1A. Risk Factors" section in our 2025 Q1 Form 10-Q.

<u>Acquisitions</u>

We complement our organic growth with acquisitions and other investments. Acquisitions can affect our reported results, and we report the change in our Net sales between periods both from existing and acquired businesses. The change in Net sales due to acquisitions for the periods presented in this filing represents the incremental sales as a result of acquisitions. For additional information on our acquisitions, refer to Note 3, "Acquisitions" in the accompanying Notes contained elsewhere in this Form 10-Q.

<u>Foreign Currency Fluctuations</u>

A significant portion of our Net sales, 79% for the three and nine months ended October 3, 2025 are outside the United States, with the majority of those sales denominated in currencies other than the U.S. Dollar. Because much of our manufacturing and employee costs are outside the United States, a significant portion of our costs are also denominated in currencies other than the U.S. Dollar. Changes in foreign exchange rates can impact our results of operations and are quantified when significant.

For the three months ended October 3, 2025 compared to the three months ended September 27, 2024, fluctuations in foreign currencies increased Net sales by 1.5%, Gross profit by 1.6% and Selling, general and administrative expenses by 2.1%.

------

For the nine months ended October 3, 2025 compared to the nine months ended September 27, 2024, fluctuations in foreign currencies reduced Net sales by 0.6% and Gross profit by 0.2% and increased Selling, general and administrative expenses by 0.2%.

<u>Seasonality</u>

Our European operations typically experience a slowdown during the July and August vacation seasons.

*Non-GAAP Measures*

Adjusted EBITDA is a non-GAAP performance measure that we include in this Form 10-Q because it is a key metric used by our management to assess our operating performance. ESAB presents this non-GAAP financial measure including and excluding Russia due to economic and political volatility caused by the Russia and Ukraine conflict, which we believe results in enhanced investor interest in these alternative presentations. Adjusted EBITDA excludes from Net income from continuing operations the effect of Income tax expense, Interest expense and other, net, Pension settlement loss, Restructuring and other related charges, acquisition transaction, due diligence and integration expenses, amortization of intangibles and fair value charges on acquired inventories and depreciation and other amortization. We also present Adjusted EBITDA margin, which is subject to the same adjustments as Adjusted EBITDA. Further, we present these non-GAAP performance measures on a segment basis subject to the same adjustments described above. We also present Core adjusted EBITDA and Core adjusted EBITDA margin, which are subject to the same adjustments as Adjusted EBITDA and Adjusted EBITDA margin, respectively, and which removes the impact of Russia for the three and nine months ended October 3, 2025 and September 27, 2024. Adjusted EBITDA and Core adjusted EBITDA assist management in comparing our operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to unusual events or discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity and core business. Management also believes that presenting these measures allows investors to view our performance using the same measures that we use in evaluating our financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with the accounting principles generally accepted in the United States ("U.S. GAAP"). Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable U.S. GAAP financial measures.

The following tables set forth a reconciliation of Net income from continuing operations, the most directly comparable GAAP financial measure, to Adjusted EBITDA, Adjusted EBITDA margin, Core adjusted EBITDA and Core adjusted EBITDA margin by segment for the three and nine months ended October 3, 2025 and September 27, 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended October 3, 2025** | **Three Months Ended October 3, 2025** | **Three Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** | **Nine Months Ended October 3, 2025** |
| | **Americas** | **EMEA & APAC** | **Total** | **Americas** | **EMEA & APAC** | **Total** |
| | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> |
| Net income from continuing operations (GAAP) |  |  | $65.3 |  |  | $207.7 |
| &nbsp;&nbsp;Income tax expense |  |  | 17.7 |  |  | 56.5 |
| &nbsp;&nbsp;Interest expense and other, net |  |  | 23.6 |  |  | 61.4 |
| Operating income (GAAP)<sup>(1)</sup> | $45.3 | $61.3 | $106.6 | $131.0 | $194.6 | $325.6 |
| Adjusted to add: |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and other related charges<sup>(2)</sup> | 2.2 | 2.1 | 4.3 | 4.4 | 5.8 | 10.2 |
| &nbsp;&nbsp;Acquisition-amortization and other related charges<sup>(3)</sup> | 5.8 | 10.7 | 16.5 | 21.5 | 26.2 | 47.7 |
| &nbsp;&nbsp;Depreciation and other amortization | 3.9 | 8.1 | 12.0 | 11.7 | 21.8 | 33.4 |
| Adjusted EBITDA (non-GAAP)<sup>(1)</sup> | 57.3 | 82.2 | 139.5 | 168.5 | 248.4 | 416.9 |
| &nbsp;&nbsp;Adjusted EBITDA attributable to Russia (non-GAAP)<sup>(4)</sup> |  | 6.1 | 6.1 |  | 17.1 | 17.1 |
| Core adjusted EBITDA (non-GAAP)<sup>(1)</sup> | $57.3 | $76.1 | $133.4 | $168.5 | $231.2 | $399.8 |
| Adjusted EBITDA margin (non-GAAP) | 19.6% | 18.9% | 19.2% | 19.7% | 19.6% | 19.7% |
| Core adjusted EBITDA margin (non-GAAP)<sup>(5)</sup> | 19.6% | 19.3% | 19.4% | 19.7% | 20.0% | 19.9% |

---

------

 

<sup>(1)</sup> Numbers may not sum due to rounding.

<sup>(2)</sup> Includes severance and other termination benefits, including outplacement services as well as the cost of relocating associates, relocating equipment, impairment of long-lived assets and other costs in connection with the closure and optimization of facilities and product lines.

<sup>(3)</sup> Includes transaction, diligence and integration expenses totaling $6.1 million and $20.4 million for the three and nine months ended October 3, 2025, respectively, and amortization of intangibles and fair value charges on acquired inventories totaling $10.3 million and $27.3 million for the three and nine months ended October 3, 2025, respectively.

<sup>(4)</sup> Numbers calculated following the same definition as Adjusted EBITDA for total Company.

<sup>(5)</sup> Net sales were $40.4 million and $108.8 million relating to Russia for the three and nine months ended October 3, 2025, respectively.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 27, 2024** | **Three Months Ended September 27, 2024** | **Three Months Ended September 27, 2024** | **Nine Months Ended September 27, 2024** | **Nine Months Ended September 27, 2024** | **Nine Months Ended September 27, 2024** |
| | **Americas** | **EMEA & APAC** | **Total** | **Americas** | **EMEA & APAC** | **Total** |
| | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> |
| Net income from continuing operations (GAAP) |  |  | $71 |  |  | $219.5 |
| &nbsp;&nbsp;Income tax expense |  |  | 18.1 |  |  | 54.5 |
| &nbsp;&nbsp;Interest expense and other, net |  |  | 16.9 |  |  | 49.9 |
| &nbsp;&nbsp;Pension settlement loss |  |  |  |  |  | 12.2 |
| Operating income (GAAP) | $49.9 | $56.1 | $106 | $151.8 | $184.3 | $336 |
| Adjusted to add: |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring and other related charges<sup>(2)</sup> | 0.9 | 1.0 | 1.9 | 2.0 | 6.6 | 8.6 |
| &nbsp;&nbsp;Acquisition-amortization and other related charges<sup>(3)</sup> | 4.8 | 5.2 | 10.1 | 13.5 | 12.1 | 25.6 |
| &nbsp;&nbsp;Depreciation and other amortization | 3.7 | 5.7 | 9.5 | 10.9 | 16.5 | 27.4 |
| Adjusted EBITDA (non-GAAP) | 59.4 | 68.1 | 127.4 | 178.2 | 219.4 | 397.5 |
| &nbsp;&nbsp;Adjusted EBITDA attributable to Russia (non-GAAP)<sup>(4)</sup> |  | 2.6 | 2.6 |  | 15.5 | 15.5 |
| Core adjusted EBITDA (non-GAAP) | $59.4 | $65.5 | $124.8 | $178.2 | $203.9 | $382.1 |
| Adjusted EBITDA margin (non-GAAP) | 20.6% | 17.7% | 18.9% | 19.9% | 18.7% | 19.2% |
| Core adjusted EBITDA margin (non-GAAP)<sup>(5)</sup> | 20.6% | 18.9% | 19.6% | 19.9% | 19.2% | 19.5% |

---

 

<sup>(1)</sup> Numbers may not sum due to rounding.

<sup>(2)</sup> Includes severance and other termination benefits, including outplacement services as well as the cost of relocating associates, relocating equipment, impairment of long-lived assets and other costs in connection with the closure and optimization of facilities and product lines.

<sup>(3)</sup> Includes transaction, diligence and integration expenses totaling $2.5 million and $3.1 million for the three and nine months ended September 27, 2024, respectively, and amortization of intangibles and fair value charges on acquired inventories totaling $7.6 million and $22.4 million for the three and nine months ended September 27, 2024, respectively.

<sup>(4)</sup> Numbers calculated following the same definition as Adjusted EBITDA for total Company.

<sup>(5)</sup> Net sales were $37.7 million and $112.0 million relating to Russia for the three and nine months ended September 27, 2024, respectively.

***Total Company***

*Sales*

The following table presents the components of changes in our Net sales for the three and nine months ended October 3, 2025 compared to the prior year period.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **Net Sales** | **Change %** | **Net Sales** | **Change %** |
| | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> |
| For the three and nine months ended September 27, 2024 | $673.3 |  | $2070.0 |  |
| &nbsp;&nbsp;&nbsp;*Components of Change:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Existing businesses (organic sales)<sup>(2)</sup> | 11.0 | 1.6% | (5.8) | (0.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions<sup>(3)</sup> | 33.8 | 5.0% | 69.5 | 3.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation<sup>(4)</sup> | 9.8 | 1.5% | (12.3) | (0.6)% |
| &nbsp;&nbsp;&nbsp;Total Net sales growth | 54.6 | 8.1% | 51.5 | 2.5% |
| For the three and nine months ended October 3, 2025 | $727.8 |  | $2121.6 |  |

---

 

<sup>(1)</sup> Numbers may not sum due to rounding.

<sup>(2)</sup> Excludes the impact of acquisitions and foreign exchange rate fluctuations, thus providing a measure of change due to organic growth factors such as price, product mix and volume.

<sup>(3)</sup> Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.

<sup>(4)</sup> Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

Net sales from existing businesses increased by $11.0 million during the three months ended October 3, 2025, compared to the prior year period, driven by increases in both price and volume. Additionally, there was an increase in net sales from acquisitions attributable to SUMIG Soluções para Solda e Corte Ltda. ("SUMIG"), Bavaria Schweisstechnik ("Bavaria"), DeltaP s.r.l. ("DeltaP"), Aktiv Technologies Private Limited ("Aktiv") and EWM GmbH ("EWM"). The changes in foreign exchange rates resulted in a $9.8 million favorable currency translation impact.

Net sales from existing businesses decreased by $5.8 million during the nine months ended October 3, 2025, compared to the prior year period, due to a $28.1 million decrease in sales volume due to drivers such as tariffs in the Americas and lower volumes in Russia partially offset by customer pricing increases of $22.3 million. The increase in net sales from acquisitions was attributable to Sager S.A., ESAB Bangladesh Private Limited ("ESAB Bangladesh"), SUMIG, Bavaria, DeltaP, Aktiv and EWM. The changes in foreign exchange rates resulted in a $12.3 million unfavorable currency translation impact.

*Sales excluding Russia*

The following table presents the components of changes in our Net sales excluding Russia ("Core sales") for the three and nine months ended October 3, 2025 compared to the prior year period.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **Core Sales**<sup>(5)</sup> | **Change %** | **Core Sales**<sup>(5)</sup> | **Change %** |
| | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> |
| For the three and nine months ended September 27, 2024 | $635.6 |  | $1958.0 |  |
| &nbsp;&nbsp;&nbsp;*Components of Change:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Existing businesses (core organic sales)<sup>(2)</sup> | 12.1 | 1.9% | 6.6 | 0.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions<sup>(3)</sup> | 33.8 | 5.3% | 69.5 | 3.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation<sup>(4)</sup> | 5.9 | 0.9% | (21.4) | (1.1)% |
| &nbsp;&nbsp;&nbsp;Total Core sales growth | 51.8 | 8.1% | 54.7 | 2.8% |
| For the three and nine months ended October 3, 2025 | $687.4 |  | $2012.7 |  |

---

 

<sup>(1)</sup> Numbers may not sum due to rounding.

<sup>(2)</sup> Excludes the impact of acquisitions and foreign exchange rate fluctuations, thus providing a measure of change due to organic growth factors such as price, product mix and volume.

<sup>(3)</sup> Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.

<sup>(4)</sup> Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

<sup>(5)</sup> Net sales relating to Russia were $40.4 million and $37.7 million for the three months ended October 3, 2025 and September 27, 2024, respectively, and $108.8 million and $112.0 million for the nine months ended October 3, 2025 and September 27, 2024, respectively.

------

Core sales from existing businesses increased by $12.1 million during the three months ended October 3, 2025, compared to the prior year period, driven by increases in both price and volume. The increase in net sales from acquisitions was attributable to SUMIG, Bavaria, DeltaP, Aktiv and EWM. The changes in foreign exchange rates resulted in a $5.9 million favorable currency translation impact.

Core Sales from existing businesses increased by $6.6 million during the nine months ended October 3, 2025, compared to the prior year period, primarily due to customer pricing increases of $20.9 million partially offset by a $14.3 million decrease in sales volume due to drivers such as tariffs in the Americas. The increase in net sales from acquisitions was attributable to Sager S.A., ESAB Bangladesh, SUMIG, Bavaria, DeltaP, Aktiv and EWM. The changes in foreign exchange rates resulted in a $21.4 million unfavorable currency translation impact.

*Operating Results*

The following table summarizes our results for the comparable periods.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** |
| Gross profit | $269.3 | $253.8 | $790.5 | $779.1 |
| Gross profit margin | 37.0% | 37.7% | 37.3% | 37.6% |
| Selling, general and administrative expense | $158.3 | $145.9 | $454.8 | $434.5 |
| Net income from continuing operations | $65.3 | $71.0 | $207.7 | $219.5 |
| Net income margin from continuing operations | 9.0% | 10.6% | 9.8% | 10.6% |
| Adjusted EBITDA (non-GAAP) | $139.5 | $127.4 | $416.9 | $397.5 |
| Adjusted EBITDA margin (non-GAAP) | 19.2% | 18.9% | 19.7% | 19.2% |
| Core adjusted EBITDA (non-GAAP) | $133.4 | $124.8 | $399.8 | $382.1 |
| Core adjusted EBITDA margin (non-GAAP) | 19.4% | 19.6% | 19.9% | 19.5% |
| Items excluded from Adjusted EBITDA: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other related charges<sup>(1)</sup> | $4.3 | $1.9 | $10.2 | $8.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-amortization and other related charges<sup>(2)</sup> | 16.5 | 10.1 | 47.7 | 25.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense and other, net | 23.6 | 16.9 | 61.4 | 49.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 17.7 | 18.1 | 56.5 | 54.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension settlement loss |  |  |  | 12.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and other amortization | 12.0 | 9.5 | 33.4 | 27.4 |
| Items excluded from Core adjusted EBITDA: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA attributable to Russia (non-GAAP)<sup>(3)</sup> | $6.1 | $2.6 | $17.1 | $15.5 |

---

 

<sup>(1)</sup> Includes severance and other termination benefits, including outplacement services as well as the cost of relocating associates, relocating

equipment, lease termination, impairment of long-lived assets and other costs in connection with the closure of and optimization of facilities and product lines.

<sup>(2)</sup> Includes transaction, diligence and integration expenses totaling $6.1 million and $20.4 million for the three and nine months ended October 3, 2025, respectively, and $2.5 million and $3.1 million for the three and nine months ended September 27, 2024, respectively. Additionally, it includes amortization of intangibles and fair value charges on acquired inventories totaling $10.3 million and $27.3 million for the three and nine months ended October 3, 2025, respectively, and $7.6 million and $22.4 million for the three and nine months ended September 27, 2024, respectively.

<sup>(3)</sup> Numbers calculated following the same definition as Adjusted EBITDA for total Company.

<u>Third Quarter of 2025 Compared to Third Quarter of 2024</u>

Gross profit increased by $15.5 million in the third quarter of 2025 compared to the prior year period primarily attributable to acquisitions, favorable foreign exchange and price increases partially offset by higher material costs. The decline of gross profit margin was primarily due to the dilutive effect in the Americas segment, which was caused by customer pricing in response to tariff-related cost increases, leading to margin compression. Selling, general and administrative expense increased by $12.4 million in the third quarter of 2025 compared to the prior year period primarily due to acquisitions and related transaction costs partially offset by benefits from EBX driven savings. The effective tax rate of 21.3% for the quarter ended

------

October 3, 2025 differed from the effective tax rate of 20.3% for the same period ended September 27, 2024 due to an agreement with a taxing authority on the treatment of subsidy income in a foreign jurisdiction in 2024.

Net income from continuing operations decreased $5.7 million primarily due to higher Interest expense and other, net mainly driven by a higher Debt balance related to acquisitions. For additional information on the Interest expense and other, net impact, refer to Note 10, "Debt" and Note 11, "Derivatives" in the accompanying Notes contained elsewhere in this Form 10-Q. Adjusted EBITDA increased $12.1 million and related margin expanded 30 basis points compared to the same period in the prior year. Core adjusted EBITDA increased $8.6 million compared to the same period in the prior year.

<u>Nine Months Ended October 3, 2025 Compared to Nine Months Ended September 27, 2024</u>

Gross profit increased $11.4 million in the nine months ended October 3, 2025 compared to the prior year period primarily attributable to acquisitions, favorable foreign exchange and price increases partially offset by higher material costs, including tariffs, product mix and a decrease in sales volume. The decline of gross profit margin was primarily due to the dilutive effect in the Americas segment, which was caused by customer pricing in response to tariff-related cost increases, leading to margin compression. Selling, general and administrative expense increased $20.3 million in the nine months ended October 3, 2025 compared to the prior year period primarily due to acquisitions and related transaction costs partially offset by benefits from EBX driven savings and restructuring initiatives. The effective tax rate of 21.4% for the nine months ended October 3, 2025 differed from the effective tax rate of 19.9% for the same period ending September 27, 2024 due to discrete tax adjustments in 2024 for a favorable final ruling in a tax case in a foreign jurisdiction and an agreement with a taxing authority on the treatment of subsidy income in a foreign jurisdiction.

Net income from continuing operations decreased $11.8 million in the nine months ended October 3, 2025 compared to the prior year period primarily due to the aforementioned factors as well as higher Interest expense and other, net largely driven by a higher Debt balance related to acquisitions partially offset by the $12.2 million non-cash pension settlement loss in 2024. For additional information on the Interest expense and other, net impact, refer to Note 10, "Debt" and Note 11, "Derivatives" in the accompanying Notes contained elsewhere in this Form 10-Q. Adjusted EBITDA increased $19.4 million and Adjusted EBITDA margin expanded by 50 basis points in the nine months ended October 3, 2025 compared to the prior year period. Core adjusted EBITDA increased by $17.7 million compared to the same period in the prior year.

***Reportable Segments***

We report results in two reportable segments: Americas and EMEA & APAC.

*Americas*

The following table summarizes selected financial data for our Americas segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** |
| Net sales | $292.7 | $288.8 | $856.1 | $894.6 |
| Gross profit | $112.2 | $114.4 | $333.4 | $348.3 |
| Gross profit margin | 38.3% | 39.6% | 38.9% | 38.9% |
| Selling, general and administrative expense | $64.6 | $63.2 | $198.0 | $194.6 |
| Adjusted EBITDA (non-GAAP) | $57.3 | $59.4 | $168.5 | $178.2 |
| Adjusted EBITDA margin (non-GAAP) | 19.6% | 20.6% | 19.7% | 19.9% |
| Items excluded from Adjusted EBITDA: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other related charges | $2.2 | $0.9 | $4.4 | $2.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition - amortization and other related charges | 5.8 | 4.8 | 21.5 | 13.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and other amortization | $3.9 | $3.7 | $11.7 | $10.9 |

---

------

<u>Third Quarter of 2025 Compared to Third Quarter of 2024</u>

Net sales in our Americas segment increased $3.9 million in the third quarter of 2025 compared with the prior year period. Net sales from existing business increased $0.4 million primarily due to pricing increases and new product initiatives partially offset by slightly lower sales volumes. The acquisition of SUMIG contributed a $7.4 million increase to Net sales from acquisitions. In addition, there was $3.9 million of unfavorable currency translation. Gross profit decreased by $2.2 million attributable to higher material costs, including tariffs, and product mix partially offset by price increases and accretion from acquisitions. The decline of gross profit margin was primarily due to the dilutive effect in the Americas segment, which was caused by customer pricing in response to tariff-related cost increases, leading to margin compression. Selling, general and administrative expense remained relatively consistent compared with the prior year. Adjusted EBITDA decreased $2.1 million primarily due to the aforementioned factors.

<u>Nine Months Ended October 3, 2025 Compared to Nine Months Ended September 27, 2024</u>

Net sales in our Americas segment decreased $38.5 million in the nine months ended October 3, 2025 compared with the prior year period. Net sales from existing business decreased $29.1 million due to reduced sales volumes primarily driven by tariffs and related impacts partially offset by pricing increases. In addition, there was $34.6 million in unfavorable currency translation. The Sager S.A. and SUMIG acquisitions contributed a $25.2 million increase to Net sales from acquisitions. Gross profit decreased $14.9 million attributable to higher material costs, including tariffs, and decreases in sales volume partially offset by acquisitions and price increases. Selling, general and administrative expense increased $3.4 million compared with the prior year period primarily due to acquisitions partially offset by benefits from EBX driven savings. Adjusted EBITDA decreased $9.7 million compared to the prior year period primarily because of the aforementioned factors.

*EMEA & APAC*

The following table summarizes the selected financial data for our EMEA & APAC segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** | **October 3, 2025** | **September 27, 2024** |
| | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** | **(Dollars in millions)** |
| Net sales | $435.1 | $384.4 | $1265.4 | $1175.4 |
| Gross profit | $157.1 | $139.4 | $457.2 | $430.8 |
| Gross profit margin | 36.1% | 36.3% | 36.1% | 36.7% |
| Selling, general and administrative expense | $93.8 | $82.6 | $256.8 | $239.9 |
| Adjusted EBITDA (non-GAAP) | $82.2 | $68.1 | $248.4 | $219.4 |
| Adjusted EBITDA margin (non-GAAP) | 18.9% | 17.7% | 19.6% | 18.7% |
| Core adjusted EBITDA (non-GAAP) | $76.1 | $65.5 | $231.2 | $203.9 |
| Core adjusted EBITDA margin (non-GAAP) | 19.3% | 18.9% | 20.0% | 19.2% |
| Items excluded from Adjusted EBITDA: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other related charges | $2.1 | $1.0 | $5.8 | $6.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition - amortization and other related charges | 10.7 | 5.2 | 26.2 | 12.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension settlement loss |  |  |  | 12.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and other amortization | 8.1 | 5.7 | 21.8 | 16.5 |
| Items excluded from Core adjusted EBITDA: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA attributable to Russia (non-GAAP) | $6.1 | $2.6 | $17.1 | $15.5 |

---

<u>Third Quarter of 2025 Compared to Third Quarter of 2024</u>

Net sales in our EMEA & APAC segment increased $50.7 million in the third quarter of 2025 compared with the prior year period. Net sales from existing business increased $10.6 million primarily resulting from increases in sales volume. Furthermore, the Bavaria, DeltaP, Aktiv and EWM acquisitions contributed $26.4 million to Net sales from acquisitions and there was a $13.7 million favorable foreign currency impact. Gross profit increased by $17.7 million in the third quarter of 2025 compared with the prior year period primarily due to acquisitions, increased sales volumes and foreign currency translation impacts partially offset by pricing decreases. Selling, general and administrative expense increased $11.2 million in the third quarter of 2025 compared with the prior year period largely due to acquisitions and related transaction costs. Adjusted EBITDA

------

increased $14.1 million and related margin expanded by 120 basis points and Core adjusted EBITDA increased to $76.1 million and the related margin expanded by 40 basis points in the third quarter of 2025 compared with the prior year period primarily because of the aforementioned factors.

<u>Nine Months Ended October 3, 2025 Compared to Nine Months Ended September 27, 2024</u>

Net sales in our EMEA & APAC segment increased $90.0 million in the nine months ended October 3, 2025 compared with the prior year period. Net sales from existing business increased $23.3 million primarily resulting from increases in sales volume. Furthermore, the ESAB Bangladesh, Bavaria, DeltaP, Aktiv and EWM acquisitions contributed $44.3 million to Net sales from acquisitions and there was a $22.4 million in favorable foreign currency impact. Gross profit increased $26.4 million in the nine months ended October 3, 2025 compared with the prior year period due to acquisitions, favorable foreign exchange impact and increased sales volumes partially offset by lower pricing. Selling, general and administrative expense increased $16.9 million in the nine months ended October 3, 2025 compared with the prior year period primarily due to acquisitions and related costs partially offset by a gain on disposition of property. Adjusted EBITDA increased $29.0 million and Adjusted EBITDA margin expanded 90 basis points and Core adjusted EBITDA increased to $231.2 million and Core adjusted EBITDA margin expanded 80 basis points in the nine months ended October 3, 2025 compared with the prior year period primarily because of the aforementioned factors.

------

**Liquidity and Capital Resources**

*Overview*

We expect to finance our working capital requirements through cash flows from operating activities. We expect that our primary ongoing requirements for cash will be for working capital, funding of acquisitions, capital expenditures, restructuring and asbestos related cash outflows, debt service and required principal payments, stock repurchase and, pending approval from the Board of Directors, payment of cash dividends.

As of October 3, 2025, we were in compliance with the covenants under the Credit Agreement and the Indenture. The Company's weighted average interest rate of borrowings under the Credit Agreement and the Indenture was 5.55%, excluding accretion of deferred financing fees. As of the end of the third quarter, we had the capacity for additional indebtedness of up to $490 million available on the Revolving Facility, subject to meeting financial covenants and other requirements. Additionally, we have the ability to incur $50.0 million of indebtedness pursuant to certain uncommitted credit lines, consisting of an uncommitted credit line that we have used from time to time in the past for short-term working capital needs. After the quarter ended October 3, 2025, on October 16, 2025, the Company entered into an Amended and Restated Credit Agreement that, among other things, provides for (i) a senior term loan A facility in an aggregate principal amount of $350 million, and (ii) a senior revolving credit facility in the amount of $1.05 billion to replace the Company's existing $400 million Term Loan A-1 Facility and $750 million Revolving Facility and pay off the outstanding principal and interest thereunder. Both facilities mature on October 16, 2030, subject to a springing maturity date under certain circumstances. Refer to Note 10, "Debt," "Note 16, Subsequent Events" and "Note 11, "Derivatives" in the accompanying Notes contained elsewhere in this Form 10-Q for more information related to the Facilities and derivative instruments. We believe that we could raise additional funds in the form of debt or equity if it were determined to be appropriate for strategic acquisitions or other corporate purposes. We believe that our sources of liquidity between debt and cash flows from operating activities are adequate to fund our operations for the next twelve months and thereafter.

*Stock Repurchase Program*

On August 13, 2024, the Board of Directors authorized and approved a stock repurchase program to repurchase up to five million shares of the Company's Common stock, par value $0.001 per share, from time-to-time on the open market, in privately negotiated transactions or as may otherwise be determined by the Company's management in its discretion. No repurchases of the Company's Common stock have been made through the nine months ended October 3, 2025. The timing and amount of any shares repurchased will be determined by the Company's management based on its evaluation of market conditions, applicable legal requirements and other factors. There is no term associated with the remaining repurchase authorization.

------

*Cash Flows*

As of October 3, 2025, we had $218.2 million of Cash and cash equivalents, a decrease of $31.1 million from the balance of $249.4 million as of December 31, 2024.

The following table summarizes the change in Cash and cash equivalents during the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **October 3, 2025** | **September 27, 2024** |
| | **(Dollars in millions)**<sup>(1)</sup> | **(Dollars in millions)**<sup>(1)</sup> |
| **Net cash provided by operating activities** | $163.5 | $228.5 |
| Purchases of property, plant and equipment | (27.7) | (27.1) |
| Proceeds from sale of property, plant and equipment | 4.7 | 3.5 |
| Acquisitions, net of cash received | (439.7) | (86.5) |
| Other investing | 0.5 | (4.1) |
| **Net cash used in investing activities** | (462.1) | (114.2) |
| Proceeds from borrowings on Senior Notes |  | 700.0 |
| Proceeds from borrowings on revolving credit facilities and other | 359.6 | 205.0 |
| Repayments of borrowings on Term Loans | (10.0) | (597.5) |
| Repayments of borrowings on revolving credit facilities and other | (90.4) | (236.6) |
| Payment of debt issuance costs |  | (10.4) |
| Payment of dividends | (15.8) | (12.1) |
| Distributions to noncontrolling interest holders | (3.1) | (2.6) |
| Other financing | (13.0) | (5.1) |
| **Net cash provided by financing activities** | 227.3 | 40.6 |
| Effect of foreign exchange rates on Cash and cash equivalents | 40.1 | (3.2) |
| **(Decrease) increase in Cash and cash equivalents** | $(31.1) | $151.7 |

---

 

<sup>(1)</sup> Numbers may not sum due to rounding.

Cash flows from operating activities can fluctuate significantly from period to period due to changes in working capital and the timing of payments for items such as pension funding, asbestos-related costs and restructuring program funding. Changes in significant operating cash flow items are discussed below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating cash flow for the nine months ended October 3, 2025 decreased compared to the prior year period due to higher purchases of inventory in advance of tariff, higher interest expenses and transaction costs associated with acquisition activity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Discontinued operations for the nine months ended October 3, 2025 and September 27, 2024 included outflows of $10.8 million and $12.1 million, respectively, which were primarily asbestos-related.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Restructuring initiative payments were $8.8 million and $8.3 million for the nine months ended October 3, 2025 and September 27, 2024, respectively. These payments included severance and other termination benefits, including outplacement services as well as the cost of relocating associates, relocating equipment and other costs in connection with the closure and optimization of facilities and product lines.

Cash flows used in investing activities during the nine months ended October 3, 2025 primarily comprise approximately $440 million of cash used for the acquisitions of Bavaria, DeltaP, Aktiv and EWM and during the nine months ended September 27, 2024 included approximately $87 million of cash used for the acquisition of Sager S.A. and ESAB Bangladesh.

Our Cash and cash equivalents as of October 3, 2025 included $211.5 million held in jurisdictions outside the United States. Cash repatriation of non-United States cash into the United States may be subject to withholding taxes, other local statutory restrictions and minority owner distributions.

------

**Critical Accounting Policies and Estimates**

The methods, estimates and judgments that we use in applying our critical accounting policies have a significant impact on our results of operations and financial position. We evaluate our estimates and judgments on an ongoing basis. Our estimates are based upon our historical experience, our evaluation of business and macroeconomic trends and information from other outside sources, as appropriate. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what our management anticipates, and different assumptions or estimates about the future could have a material impact on our results of operations and financial position.

There have been no other significant additions or changes to the methods, estimates and judgments included in "Management's Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies" in the 2024 Form 10-K.

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk** 

We are exposed to market risk from changes in foreign currency exchange rates and commodity prices that could impact our results of operations and financial condition. We address our exposure to these risks through our normal operating and financing activities. We do not enter into derivative contracts for trading purposes.

**Interest Rate Risk**

We entered into certain Term Loans and a Revolving Facility pursuant to the terms of the Credit Agreement. Refer to Note 10, "Debt" in the accompanying Notes contained elsewhere in this Form 10-Q for additional information regarding our Facilities. We are exposed to interest rate risk on the variable-rate term loans under these Facilities. A hypothetical increase in interest rates of 1% during the nine months ended October 3, 2025 would have increased interest expense by approximately $6 million. To mitigate our interest risk, in July 2022, we entered into two interest rate swaps to hedge approximately $600 million of our floating-rate debt. In April 2024, the Company issued the Senior Notes, the proceeds of which paid off the Term A-3 Facility. As a result, the Company terminated one of these swaps hedging only $300 million of our floating-rate debt. The remaining swap matured during the first quarter in 2025, therefore no remaining interest rate swaps remained as of quarter end. See Note 11, "Derivatives" in our Notes contained elsewhere in this Form 10-Q for additional information.

**Exchange Rate Risk**

We have manufacturing sites throughout the world and sell our products globally. As a result, we are exposed to movements in the exchange rates of various currencies against the U.S. Dollar and against the currencies of other countries in which we manufacture and sell products and services. During the nine months ended October 3, 2025, approximately 79% of our sales were derived from operations outside the United States. We have significant manufacturing operations in European countries that are not part of the Eurozone. Sales are more highly weighted toward the Euro and U.S. Dollar. We also have significant contractual obligations in U.S. Dollars that are met with cash flows in other currencies as well as U.S. Dollars. To better match revenue and expense as well as cash needs from contractual liabilities, we regularly enter into currency swaps and forward contracts.

We also face exchange rate risk from our investments in subsidiaries owned and operated in foreign countries. The effect of a change in currency exchange rates on our net investment in international subsidiaries is reflected in the AOCI component of Equity. A 10% depreciation in major currencies relative to the U.S. Dollar as of October 3, 2025 would result in a reduction in Equity of approximately $240 million. As of October 3, 2025, we have six fixed-to-fixed cross-currency swaps, which are expected to provide a hedge to a portion of our European net asset position. See Note 11, "Derivatives" in our Notes contained elsewhere in this Form 10-Q for additional information.

We also face exchange rate risk from intercompany transactions between affiliates. Although we use the U.S. Dollar as our functional currency for reporting purposes, we have manufacturing sites throughout the world, and a substantial portion of our costs are incurred and sales are generated in foreign currencies. Costs incurred and sales recorded by subsidiaries operating outside of the United States are translated into U.S. Dollars using exchange rates effective during the respective period. As a result, we are exposed to movements in the exchange rates of various currencies against the U.S. Dollar. Similarly, tax costs may increase or decrease as local currencies strengthen or weaken against the U.S. Dollar.

**Commodity Price Risk**

We are exposed to changes in the prices of raw materials used in our production processes. To manage commodity price risk, we periodically enter into fixed price contracts directly with suppliers.

------

**Item 4. Controls and Procedures** 

**Evaluation of Disclosure Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of October 3, 2025. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in providing reasonable assurance that the information required to be disclosed in this report on Form 10-Q has been recorded, processed, summarized and reported as of the end of the period covered by this report on Form 10-Q.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

A discussion of legal proceedings is incorporated by reference to Note 14, "Commitments and Contingencies" in the Notes included in Part I. Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q.

**Item 1A. Risk Factors**

In addition to the information set forth in this Quarterly Report on Form 10-Q, including under "Management Discussion and Analysis of Financial Condition and Results of Operations - Special Note Regarding Forward Looking Statements," in Part I. Item 2, you should carefully consider the factors discussed in the "Risk Factors" section of the Company's 2024 Form 10-K filed with the SEC on February 20, 2025, as updated by the "Risk Factors" section in Part II. Item 1A of the Company's Form 10-Q for the quarterly period ended April 4, 2025 filed with the SEC on May 1, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds** 

None.

**Item 3. Defaults Upon Senior Securities** 

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Trading Plans

During the three months ended October 3, 2025, none of our directors or officers adopted, modified or terminated a Rule 10b5-1 or non-Rule 10b-5 trading arrangement as defined in Item 408 of Regulation S-K.

------

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit Description</u>** |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1877322/000187732225000146/esab-arcreditagreementexec.htm)</u> | Amended and Restated Credit Agreement, dated October 16, 2025, by and among ESAB Corporation, as the lead borrower, the other loan parties from time to time party thereto, including certain subsidiaries of the Company identified therein, as guarantors, each of the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, and the co-syndication agents, joint bookrunners and joint lead arrangers named therein (incorporated by reference to Exhibit 10.1 to ESAB Corporation's Form 8-K (File No. 001-41297) as filed with the SEC on October 16, 2025). |
| <u>[31.1](exhibit311ceocertification.htm)</u> | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| <u>[31.2](exhibit312cfocertification.htm)</u> | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| <u>[32.1](exhibit321ceocertification.htm)</u> | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| <u>[32.2](exhibit322cfocertification.htm)</u> | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File - The cover page from this Quarterly Report on Form 10-Q for the quarter ended October 3, 2025 is formatted in Inline XBRL (included as Exhibit 101). |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Registrant: ESAB Corporation

By:

---

| | | |
|:---|:---|:---|
| /s/ Shyam P. Kambeyanda | President and Chief Executive Officer |  |
| Shyam P. Kambeyanda | (Principal Executive Officer) | October 29, 2025 |
| /s/ Kevin Johnson | Chief Financial Officer |  |
| Kevin Johnson | (Principal Financial Officer) | October 29, 2025 |
| /s/ Renato Negro | Controller and Chief Accounting Officer |  |
| Renato Negro | (Principal Accounting Officer) | October 29, 2025 |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS** 

I, Shyam P. Kambeyanda, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ESAB Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: October 29, 2025

---

| |
|:---|
| /s/ Shyam P. Kambeyanda |
| **Shyam P. Kambeyanda**<br>**President and Chief Executive Officer**<br>**(Principal Executive Officer)** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS** 

I, Kevin Johnson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ESAB Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: October 29, 2025

---

| |
|:---|
| /s/ Kevin Johnson |
| **Kevin Johnson**<br>**Chief Financial Officer**<br>**(Principal Financial Officer)** |

---

## Exhibit 32.1

**Exhibit 32.1** 

**Certification Pursuant to 18 U.S.C. Section 1350** 

**(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)** 

I, Shyam P. Kambeyanda, as President and Chief Executive Officer of ESAB Corporation (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the quarterly report on Form 10-Q of the Company for the period ended October 3, 2025 (the "Report"), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 29, 2025

---

| |
|:---|
| /s/ Shyam P. Kambeyanda |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Shyam P. Kambeyanda**<br>**President and Chief Executive Officer**<br>**(Principal Executive Officer)** |

---

## Exhibit 32.2

**Exhibit 32.2**

**Certification Pursuant to 18 U.S.C. Section 1350** 

**(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)** 

I, Kevin Johnson, as Executive Vice President, Finance, Chief Financial Officer of ESAB Corporation (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the quarterly report on Form 10-Q of the Company for the period ended October 3, 2025 (the "Report"), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 29, 2025

---

| |
|:---|
| /s/ Kevin Johnson |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Kevin Johnson** <br>**Chief Financial Officer**<br>**(Principal Financial Officer)** |

---

<br>